

Bacterial catabolism of β -hydroxypropiovanillone and β -hydroxypropiosyringone produced in the reductive cleavage of arylglycerol- β -aryl ether in lignin

Running title: *Downstream pathway of the β -aryl ether catabolism*

Yudai Higuchi,^a Shogo Aoki,^a Hiroki Takenami,^a Naofumi Kamimura,^a Kenji Takahashi,^a Shojiro Hishiyama,^b Christopher S. Lancefield,^c O. Stephen Ojo,^c Yoshihiro Katayama,^d Nicholas J. Westwood,^c Eiji Masai^a

Department of Bioengineering, Nagaoka University of Technology, Nagaoka, Niigata, Japan^a; Forestry and Forest Products Research Institute, Tsukuba, Ibaraki, Japan^b; School of Chemistry and Biomedical Sciences Research Complex, University of St Andrews and EaStCHEM, North Haugh, St Andrews, Fife, UK^c; College of Bioresource Sciences, Nihon University, Fujisawa, Kanagawa, Japan^d.

Address correspondence to Eiji Masai, emasai@vos.nagaokaut.ac.jp

ABSTRACT

Sphingobium sp. strain SYK-6 converts four stereoisomers of arylglycerol- β -guaiacyl ether into achiral β -hydroxypropiovanillone (HPV) via three stereospecific reaction steps. Here we determined the HPV catabolic pathway and characterized the HPV catabolic genes involved in the first two steps of the pathway. In SYK-6 cells, HPV was oxidized to vanilloyl acetic acid (VAA) via vanilloyl acetaldehyde (VAL). The resulting VAA was further converted into vanillate through the activation of VAA by coenzyme A. A syringyl-type HPV analog, β -hydroxypropiosyringone (HPS), was also catabolized via the same pathway. SLG_12830 (*hvpZ*), which belongs to the glucose-methanol-choline oxidoreductase family, was isolated as the HPV-converting enzyme gene. An *hvpZ* mutant completely lost the ability to convert HPV and HPS, indicating that *hvpZ* is essential for the conversion of both the substrates. HvpZ produced in *Escherichia coli* oxidized both HPV and HPS, and other 3-phenyl-1-propanol derivatives. HvpZ localized to both the cytoplasm and membrane of SYK-6 and used ubiquinone derivatives as electron acceptors. Thirteen gene products of the 23 aldehyde dehydrogenase (ALDH) genes in SYK-6 were able to oxidize VAL into VAA. Mutant analyses suggested that multiple ALDH genes, including SLG_20400, contribute to the conversion of VAL. We examined whether the genes encoding feruloyl-CoA synthetase (*ferA*) and feruloyl-CoA hydratase/lyase (*ferB* and *ferB2*) are involved in the conversion of VAA. Only FerA exhibited activity toward VAA; however, disruption of *ferA* did not affect VAA conversion. These results indicate that another enzyme system is involved in VAA conversion.

IMPORTANCE

Cleavage of the β -aryl ether linkage is the most essential process in lignin biodegradation. Although the bacterial β -aryl ether cleavage pathway and catabolic genes have been well documented, there have been no reports regarding the catabolism of HPV or HPS, the products of cleavage of β -aryl ether compounds. HPV and HPS have also been found to be obtained from lignin by chemoselective catalytic oxidation by 2,3-dichloro-5,6-dicyano-1,4-benzoquinone/*tert*-butyl nitrite/O₂, followed by cleavage of the β -aryl ether with zinc. Therefore, value-added chemicals are expected to be produced from these compounds. In this study, we determined the SYK-6 catabolic pathways for HPV and HPS, and identified the catabolic genes involved in the first two steps of the pathways. Since SYK-6 catabolizes HPV through 2-pyrone-4,6-dicarboxylate, which is a building block for functional polymers, characterization of HPV catabolism is important not only for understanding the bacterial lignin catabolic system but also for lignin utilization.

KEYWORDS

Sphingobium, lignin, β -aryl ether, glucose-methanol-choline oxidoreductase, aldehyde dehydrogenase

INTRODUCTION

Lignin, one of the major components of plant cell walls, is a complex phenolic heteropolymer produced from hydroxycinnamyl alcohols by radical coupling (1, 2). Lignin is the second most abundant bioresource on earth after cellulose and is expected to be used as an industrial raw material. However, the current industrial applications of lignin are limited to low value applications such as production of solid fuels and concrete additives (3, 4). On the other hand, it has been reported that the building blocks for functional polymers, such as 2-pyrone-4,6-dicarboxylic acid (5-7), *cis,cis*-muconic acid (8-10), and medium chain-length polyhydroxyalkanoic acid (11), can be obtained from lignin-derived aromatic compounds such as vanillic acid, vanillin, ferulic acid, and *p*-coumaric acid through microbial catabolism. Therefore, production of value-added chemicals from lignin through transformations systems that consist of chemical lignin decomposition and microbial catabolism of lignin-derived aromatics has attracted attention.

β -Aryl ether is the most abundant linkage in lignin, comprising 45%–50% of all linkages in softwood lignin and 60%–62% in hardwood lignin (4). Accordingly, degradation of this structure is considered a crucial step in lignin biodegradation. β -Aryl ether-type biaryls have two distinct isomeric forms, *erythro* and *threo*, each of which has enantiomeric forms (12). To date, the whole picture of the enzyme system for the cleavage of β -aryl ether in *Sphingobium* sp. strain SYK-6 has been determined (13). SYK-6 is able to degrade all the stereoisomers of β -aryl ether-type biaryl, guaiacylglycerol- β -guaiacyl ether (GGE). In SYK-6 cells, four stereoisomers of GGE are converted to two enantiomers of α -(2-methoxyphenoxy)- β -hydroxypropiovanillone (MPPV) through the oxidation of the GGE α -carbon atom catalyzed by C α -

dehydrogenases (LigD, LigL, and LigN) (Fig. 1) (14). LigD oxidizes ($\alpha R, \beta S$)-GGE and ($\alpha R, \beta R$)-GGE into (βS)-MPHPV and (βR)-MPHPV, respectively, while LigL/LigN converts ($\alpha S, \beta R$)-GGE and ($\alpha S, \beta S$)-GGE into (βR)-MPHPV and (βS)-MPHPV, respectively (14). The ether linkage of the resulting MPHPV is cleaved by enantioselective glutathione *S*-transferases (GSTs), LigF, LigE, and LigP, to produce α -glutathionyl- β -hydroxypropiovanillone (GS-HPV) and guaiacol via nucleophilic attack of glutathione on the MPHPV β -carbon atom (15, 16). LigF and LigE/LigP attack (βS)-MPHPV and (βR)-MPHPV to produce (βR)-GS-HPV and (βS)-GS-HPV, respectively. Another GST, LigG, catalyzes the cleavage of the thioether linkage in (βR)-GS-HPV by transferring glutathione of (βR)-GS-HPV to another glutathione molecule to produce HPV and glutathione disulfide (15, 17). On the other hand, LigG had little to no activity with (βS)-GS-HPV, suggesting involvement of an alternative GST in the conversion of (βS)-GS-HPV (15, 18). Recently, further detailed biochemical characterization of the β -aryl ether catabolic enzymes of SYK-6 and their orthologs in other bacterial strains, and structural analyses of LigD, LigL, LigE, LigF, and LigG have been performed (17-29). In addition, *Erythrobacter* sp. strain SG61-1L and *Novosphingobium* sp. strain MBES04, which are capable of cleaving β -aryl ether, have recently been isolated, and similar enzyme systems have been characterized (23, 24).

Although many investigations of the cleavage of β -aryl ether have been performed, there are no reports on the characterization of the catabolism of HPV, the product of the cleavage of β -aryl ether. Therefore, for understanding bacterial β -aryl ether catabolism, it is essential to elucidate the HPV catabolic system. Recently, the production of HPV and β -hydroxypropiosyringone (HPS; an intermediate metabolite of syringyl-type β -aryl ether) from lignin has been attempted through biological and

chemical processes for the purpose of obtaining phenolic monomers from lignin (27, 30). Ohta et al. reported that HPV and HPS could be obtained from milled wood lignin from Japanese cedar (*Cryptomeria japonica*) and *Eucalyptus globulus* after reactions with MBES04 enzymes (27). Lancefield et al. reported an isolation method for HPV and HPS from Birch lignin via catalytic oxidation of the β -aryl ether linkage in lignin followed by zinc-mediated cleavage of the ether bonds (30). By combining these decomposition methods with microbial catabolism of HPV and HPS, development of a production system for value-added chemicals from lignin is expected.

In this study, we determined the catabolic pathway of HPV and HPS in SYK-6, and characterized the genes involved in the first two steps of the pathway.

99 **RESULTS AND DISCUSSION**

100 **Determination of the pathway for the catabolism of HPV and HPS in *Sphingobium***
101 **sp. SYK-6.** In order to determine the catabolic pathway of HPV in SYK-6, intermediate
102 metabolites generated during the incubation of HPV with resting cells of SYK-6 were
103 identified. Resting cells of SYK-6 grown in Wx minimal medium (31) containing 10
104 mM sucrose, 10 mM glutamate, 0.13 mM methionine, and 10 mM proline (Wx-SEMP)
105 were incubated with 1 mM HPV for 6 h, and the reaction mixtures were analyzed by
106 high-performance liquid chromatography-mass spectrometry (HPLC-MS). This analysis
107 indicated that HPV was converted into compound I with a retention time of 3.1 min
108 (Fig. 2B). Based on a comparison of the retention time and m/z value of the
109 deprotonated ion of compound I with those of the authentic sample, this compound was
110 identified as vanillic acid (molecular weight [Mw], 168) (Fig. 2C and Fig. S1A and B).
111 Next, a cell extract (>10 kDa) of SYK-6 cells grown in Wx-SEMP was incubated with
112 200 μ M HPV for 24 h. HPLC-MS analysis of the reaction mixture showed that HPV
113 was converted into compound II with a retention time of 2.9 min (Fig. 2E). Positive
114 electrospray ionization (ESI)-MS analysis of compound II showed a major fragment at
115 m/z 298 (Fig. 2F). Based on the molecular weight deduced from the major fragment ion
116 and additives in the reaction mixture, compound II was identified as an imine derivative
117 of vanilloyl acetaldehyde (VAL), 2-((3-hydroxy-3-(4-hydroxy-3-
118 methoxyphenyl)allylidene)amino)-2-(hydroxymethyl)propane-1,3-diol or its
119 oxazolidine product (VAL-Tris; Mw, 297; Fig. S1C and D). It is known that some
120 aldehyde substrates such as glyceraldehyde 3-phosphate, acetaldehyde, and
121 benzaldehyde react with tris(hydroxymethyl)aminomethane (Tris) to form imine
122 product, which is then trapped by one of the free hydroxyl groups forming an

oxazolidine product (32). Furthermore, Fukuzumi et al. attempted to synthesize VAL by Claisen-Wislicenus hydroxymethylene condensation between acetovanillone and ethyl formate in the presence of metallic sodium; however, *cis*-vanilloyl vinyl alcohol, a tautomer of VAL, was obtained as a major product (33). It was thought that VAL had five possible tautomers, and the form of hydroxyl vinyl ketone structure (vanilloyl vinyl alcohol) was stable (33). These observations suggested that VAL-Tris (imine product) was produced from HPV through oxidation of C γ -alcohol catalyzed by the SYK-6 cell extract to generate VAL, and to result in the isomerization of VAL and condensation between a VAL isomer and Tris in the reaction buffer. VAL-Tris (imine product) was then possibly converted to the oxazolidine product.

When a SYK-6 cell extract (>10 kDa) was incubated with 200 μ M HPV in the presence of 500 μ M NAD⁺ for 2 h, an accumulation of compound III with a retention time of 4.7 min was observed (Fig. 2G). Negative ESI-MS analysis of compound III showed fragments at *m/z* 209 and 165 (Fig. 2I). Since these fragments seemed to represent the deprotonated ion and its decarboxylated ion, respectively compound III was identified to be vanilloyl acetic acid (VAA; Mw, 210; Fig. S1E and F). VAL seems to be transformed to VAA by NAD⁺-dependent aldehyde dehydrogenase(s) (ALDHs) (Fig. 1). Additionally, when the same reaction mixture was incubated for 24 h, compound IV with a retention time of 5.8 min was generated (Fig. 2H). A comparison of the retention time and *m/z* value of the protonated ion with those of the authentic sample indicated that compound IV was acetovanillone (Mw, 166; Fig. 2L and Fig. S1G and H). Previously, Niwa and Saburi reported that VAA was spontaneously decarboxylated to acetovanillone (Fig. 1) (34).

Because lignin-derived aromatic acids such as ferulate, *p*-coumarate, and caffeate

are catabolized via CoA-dependent pathways, we predicted that VAA is catabolized through its C γ activation by coenzyme A (CoA) (35-39). A SYK-6 cell extract (>10 kDa) was therefore incubated with 200 μ M HPV in the presence of 500 μ M NAD⁺, 2 mM CoA, 2.5 mM MgSO₄, and 2.5 mM ATP. After incubation for 2 h, a decrease in HPV and an accumulation of VAA (compound III) were observed (Fig. 2J). After further incubation for 24 h, vanillic acid (compound I) and acetovanillone (compound IV) were observed (Fig. 2K). Vanillic acid was generated only when CoA, ATP, and MgSO₄ were present. This result strongly suggested that VAA was converted to vanillate through the CoA derivative of VAA (Fig. 1).

Similarly, we examined the SYK-6 catabolic pathway of HPS. Resting SYK-6 cells grown in Wx-SEMP were incubated with 1 mM HPS for 4 h, and the reaction mixtures were analyzed by HPLC-MS. This analysis indicated that HPS was converted into compound V with a retention time of 2.6 min (Fig. 3B). Negative ESI-MS analysis of compound V showed a major fragment at m/z 197 (Fig. 3C). Based on a comparison of the retention time and m/z value of the deprotonated ion with those of the authentic sample, compound V was identified as syringic acid (Mw, 198; Fig. S1I and J). In order to clarify the more detailed catabolic pathway of HPS, cell extracts (>10 kDa) prepared from SYK-6 cells grown in Wx-SEMP were incubated with 200 μ M HPS for 16 h. An accumulation of compound VI with a retention time of 1.8 min was observed (Fig. 3E). Negative ESI-MS analysis of compound VI showed a major fragment at m/z 326 (Fig. 3F), suggesting the formation of an imine derivative of 3-(4-hydroxy-3,5-dimethoxyphenyl)-3-oxopropanal (designated SAL), 2-((3-hydroxy-3-(4-hydroxy-3,5-dimethoxyphenyl)allylidene)amino)-2-(hydroxymethyl)propane-1,3-diol or its oxazolidine product (SAL-Tris; Mw, 327).

In the presence of 500 μ M NAD^+ , the same cell extract (>10 kDa) converted HPS into SAL-Tris (compound VI) and compound VII with a retention time of 3.3 min (Fig. 3H). Negative ESI-MS analysis of compound VII showed fragments at m/z 239 and 195, which seemed to represent the deprotonated ion and its decarboxylated ion, respectively (Fig. 3I). From these results, compound VII was identified as 3-(4-hydroxy-3,5-dimethoxyphenyl)-3-oxopropanoic acid (designated SAA; Mw, 240). These results indicate that HPS was oxidized to SAA via SAL, and may be degraded by the same enzyme system involved in HPV catabolism (Fig. 1).

Basic properties of the enzyme involved in the conversion of HPV. In order to characterize the enzymes involved in the catabolism of HPV in SYK-6, cofactor requirements and induction profiles of the HPV-transforming activities in SYK-6 were examined. The effects of the addition of 1-methoxy-5-methylphenazinium methylsulfate (PMS), flavin adenine dinucleotide (FAD) + PMS, and NAD^+ on the enzyme activities in converting 200 μ M HPV were investigated. When an extract of SYK-6 cells grown in Wx-SEMP was incubated with HPV in the presence of PMS, the extract showed 1.8-fold higher activity ($4.2 \pm 0.7 \text{ nmol} \cdot \text{min}^{-1} \cdot \text{mg}^{-1}$) than that in the absence of cofactors ($2.4 \pm 0.8 \text{ nmol} \cdot \text{min}^{-1} \cdot \text{mg}^{-1}$). On the other hand, the addition of FAD or NAD^+ had no effect on the activity. These results suggested that an oxidase(s) that requires an electron acceptor is involved in HPV oxidation. The HPV-oxidizing activity of an extract of SYK-6 cells grown with GGE was also measured in the presence of PMS. However, no activation was observed, suggesting the constitutive expression of the gene(s) responsible for the oxidation of HPV.

Isolation of the gene involved in the conversion of HPV. A cosmid library of SYK-6 constructed in *Sphingomonas sanguinis* IAM 12578 was screened for clones capable of degrading HPV. Of the 1,000 clones tested, three transconjugants degraded HPV, and cosmids pSA53, pSA88, and pSA684 were isolated. Southern hybridization analysis of the cosmid clones using Sall-digested pSA53 as a probe suggested that a 3.6 kb, a 2.0 kb, and two 1.0 kb Sall fragments were commonly present in the above cosmids. Subcloning and nucleotide sequencing showed that these Sall fragments were present in a 17.9 kb DNA fragment that contained 13 genes corresponding to SLG_12790 through to SLG_12910. In this fragment, SLG_12830 revealed 36%–39% amino acid sequence identity with the glucose-methanol-choline (GMC) oxidoreductase family enzymes, including 3-(2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-7-methoxy-2,3-dihydrobenzofuran-5-yl)acrylic acid (DCA-C) oxidases (PhcC and PhcD) involved in the catabolism of dehydrodiconiferyl alcohol (DCA) in SYK-6 (40), AlkJ, which is involved in the oxidation of primary alcohols to aldehydes in *Pseudomonas putida* GPo1 (41), and polyethylene glycol dehydrogenase (PegA) of *Sphingopyxis terrae* (42).

The gene product of SLG_12830 catalyzes oxidation of HPV. SLG_12830 fused with a His tag at the 5' terminus was co-expressed in *E. coli* with the trigger factor chaperone. Sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) of a cell extract prepared from *E. coli* harboring pCold12830 and pTf16 (*hvpZ*-expressing *E. coli*) showed the expression of SLG_12830 (Fig. S2). In order to determine the reaction product, resting cells of the *E. coli* transformant were incubated with 200 μ M HPV in Tris-HCl buffer. HPLC-MS analysis showed that HPV was almost

completely converted, and that VAL-Tris and compound VIII with a retention time of 5.4 min were produced (Fig. 4A). When the same incubation was performed in water, a significant amount of compound VIII was observed without the generation of VAL-Tris (Fig. 4B). Positive ESI-MS analysis of compound VIII showed a major fragment at m/z 195 (Fig. 4C), suggesting that compound VIII was VAL (Mw, 194). These results indicated that the gene product of SLG_12830 has the ability to oxidize HPV into VAL.

Role of SLG_12830 in HPV and HPS catabolism. In order to examine whether SLG_12830 is indeed involved in the conversion of HPV in SYK-6, an SLG_12830 mutant (SME059) was created (Fig. S3A and B). The ability of SME059 to convert HPV was assessed using resting cells. SME059 was no longer able to convert HPV, whereas the wild type completely converted 200 μ M HPV within 3 h (Fig. 4D). When GGE was used as a substrate, the conversion rates of the wild type and SME059 were almost identical (Fig. 4E). However, only SME059 accumulated HPV at a concentration approximately equimolar to the added GGE (Fig. 4E). In addition, SME059 also completely lost the ability to convert HPS (Fig. 4F). The HPV conversion defect of SME059 was complemented by the introduction of pJB12830 carrying SLG_12830 (Fig. 4G). These results demonstrated that GGE is catabolized through HPV in SYK-6, and SLG_12830 is essential for the catabolism of HPV and HPS; thus, we designated this gene *hvpZ*.

Cellular localization of HvpZ. In order to determine the cellular localization of HvpZ, HPV-transforming activities of soluble and membrane fractions of SYK-6 cells were compared. The HPV transforming activity in the cytoplasmic and membrane

fractions were estimated to be 0.6 ± 0.1 nmol·min⁻¹ (7.5 mg of protein) and 0.5 ± 0.1 nmol·min⁻¹ (0.9 mg of protein), respectively, based on the results that the ratio of the amount of proteins in the soluble and membrane fractions was 75:9.4 (40). These results indicated that HpvZ is localized to cytoplasm and cytoplasmic membrane. Similarly, GMC oxidoreductase family proteins, PhcC and PhcD from SYK-6, and PegA from *S. terrae*, have been suggested to localize to both the soluble and membrane fractions (40, 43). Another GMC oxidoreductase family protein, AlkJ from *P. putida* GPo1, and glucose dehydrogenase from *Pseudomonas fluorescens*, were localized to the membrane (41, 44). Since there are no predicted signal sequences or hydrophobic transmembrane segments in the deduced amino acid sequence of HpvZ, this enzyme appears to be a peripheral cytoplasmic membrane protein like other membrane-associated GMC oxidoreductase family enzymes.

Enzyme properties of HpvZ. Cell extracts prepared from *hvpZ*-expressing *E. coli* were fractionated into the soluble and membrane fractions. SDS-PAGE of both fractions showed the expression of *hvpZ* (Fig. S2). The specific activity for HPV of the membrane fraction was estimated to be 26 ± 6 nmol·min⁻¹·mg⁻¹. However, the soluble fraction showed no activity even in the presence of PMS. The membrane fraction was treated with each of ten different detergents, and the solubilized HpvZ was obtained from the membrane fractions treated with *n*-dodecylphosphocholine and 5-cyclohexyl-1-pentyl- β -D-maltoside. However, purified HpvZ was not obtained due to the lack of adsorption of the enzyme to a nickel affinity column. Therefore, the enzyme properties of HpvZ were examined using the membrane fraction prepared from extracts of *hvpZ*-expressing *E. coli* cells.

The optimum pH and temperature for the activity of HpvZ were determined to be pH 8.5–9.0 and at 40°C–45°C, respectively (Fig. S4).

The substrate range of HpvZ was examined using 200 μ M of HPV, HPS, coniferyl alcohol, sinapyl alcohol, cinnamyl alcohol, 3-(4-hydroxyphenyl)-1-propanol, homovanillyl alcohol, vanillyl alcohol, GGE, MPHPV, DCA, and DCA-C (Fig. S5).

HPLC analyses of the reaction mixtures indicated that HpvZ showed no activity for a C₆–C₂ monomeric alcohol (homovanillyl alcohol), a C₆–C₁ monomeric alcohol (vanillyl alcohol), and lignin-derived biaryls, including GGE, MPHPV, and DCA-C (Table 1). On the other hand, HpvZ showed activities toward all of the C₆–C₃ monomeric alcohols (3-phenyl-1-propanol derivatives; Table 1). Generally, GMC oxidoreductase family enzymes act on hydroxyl groups of alcohols, carbohydrates, or sterols (45). For example, an aryl-alcohol oxidase from *Pleurotus eryngii* is able to oxidize a variety of aromatic alcohols and aldehydes, including coniferyl alcohol and cinnamyl alcohol (46). On the contrary, PhcC and PhcD specifically oxidize the alcohol group at C γ of the A-ring side chain of DCA-C and DCA, although PhcC has a weak activity for coniferyl alcohol (40). HpvZ was able to oxidize the alcohol group at C γ of the B-ring side chain of DCA, which is different from the regiospecificity of PhcC and PhcD (data not shown).

Among the enzymes belonging to the GMC oxidoreductase family, an FAD-binding domain (GMC_oxred_N; PF00732) is conserved in the N-terminal region. This domain includes the typical GxGxxG/A sequence motif, which is indicative of the Rossmann fold involved in binding the ADP moiety of FAD (47). A substrate-binding domain is also conserved in the C-terminal region, although this domain is less conserved. In addition, an active-site histidine, which can assist in substrate oxidation

and FAD reoxidation by molecular oxygen, is generally conserved (45, 47). These domains and the residue are also conserved in HpvZ (Fig. S6). To identify the flavin cofactor in HpvZ, a supernatant obtained by heat treating the membrane fraction containing HpvZ was analyzed by HPLC. However, a significant peak was not observed. Furthermore, the specific activities in the presence of FAD ($26 \pm 8 \text{ nmol} \cdot \text{min}^{-1} \cdot \text{mg}^{-1}$) or flavin mononucleotide ($27 \pm 1 \text{ nmol} \cdot \text{min}^{-1} \cdot \text{mg}^{-1}$) were almost equivalent to that in the absence of any flavin cofactors ($26 \pm 6 \text{ nmol} \cdot \text{min}^{-1} \cdot \text{mg}^{-1}$). GMC oxidoreductase family enzymes generally contain either covalently or non-covalently bound FAD (45). Choline oxidase from *Arthrobacter globiformis* (48) and pyranose dehydrogenase (*AmPDH*) from *Agaricus meleagris* (49) have covalently bound FAD. Our results suggested that HpvZ may also covalently bind to FAD. Moreover, although purified inactive HpvZ was obtained from the soluble fraction of the *hvpZ*-expressing *E. coli* cells, UV-visible spectra of the enzyme showed no absorption at 454 nm, indicating the absence of flavin cofactor in the enzyme (data not shown). This result suggested that HpvZ produced in the *E. coli* cytoplasm lacked FAD as a prosthetic group.

***In vivo* electron acceptor of HpvZ.** AlkJ and PegA are able to use ubiquinone (CoQ_{10}) and its derivatives (CoQ_0 and CoQ_1) as electron acceptors for the oxidation of their substrates (41, 42). PhcC and PhcD have also been shown to be able to use CoQ_0 and CoQ_1 as electron acceptors as well as PMS (40). Furthermore, electron transport from AlkJ to cytochrome *c* in the presence of CoQ_1 has been observed (41). Therefore, the electrons that are removed from the substrate by AlkJ, PegA, and PhcC/PhcD are thought to be transferred to the respiratory chain. Based on these observations, we predicted that HpvZ could use ubiquinone as an electron acceptor in the oxidation of

HPV. When using a membrane fraction of SYK-6 cells harboring pJB12830 (*hvpZ*-expressing SYK-6), HvpZ showed 1.2- and 1.6-fold higher specific activities in the presence of CoQ₀ ($27 \pm 2 \text{ nmol} \cdot \text{min}^{-1} \cdot \text{mg}^{-1}$) and CoQ₁ ($36 \pm 6 \text{ nmol} \cdot \text{min}^{-1} \cdot \text{mg}^{-1}$), respectively, than that in the absence of cofactors ($22 \pm 1 \text{ nmol} \cdot \text{min}^{-1} \cdot \text{mg}^{-1}$). The specific activity in the presence of CoQ₁ was almost equivalent to that obtained using PMS ($40 \pm 3 \text{ nmol} \cdot \text{min}^{-1} \cdot \text{mg}^{-1}$). These results suggested that HvpZ is able to use ubiquinone as an electron acceptor *in vivo*. However, no increase in HvpZ activity was observed when the membrane fraction of *hvpZ*-expressing *E. coli* was used. The difference in the increase in HvpZ activities between the membrane fractions of *hvpZ*-expressing SYK-6 and *E. coli* cells in the presence of ubiquinone derivatives may be caused by a difference in the abundance of ubiquinone in their membrane fractions employed.

Identification of the ALDH genes responsible for the conversion of VAL. To obtain more information on the properties of the enzymes involved in the conversion of VAL in SYK-6, cofactor requirements of the enzyme activity were examined. Cell extracts (>10 kDa) of SYK-6 grown in lysogeny broth (LB) were incubated with 200 μM HPV in the presence of FAD, NAD⁺, and NADP⁺ for 2 h. In the presence of NAD⁺ and NADP⁺, VAA accumulated to levels of $95 \pm 9 \text{ } \mu\text{M}$ and $86 \pm 6 \text{ } \mu\text{M}$, respectively, while the accumulation of VAA was not observed in the presence of FAD. These results suggested that NAD⁺/NADP⁺-dependent ALDHs play a major role in VAL oxidation.

Previously, 23 ALDH genes were predicted to be present in the SYK-6 genome (50, 51). To examine the ability of the putative 23 ALDH gene products to oxidize VAL, these genes were expressed in *E. coli* using expression plasmids constructed in a

previous study (51). SDS-PAGE showed sufficient gene expression except for SLG_32240 and SLG_34940 (Fig. S7). Since HPV was converted to VAL-Tris during incubation with HpvZ in Tris-HCl buffer, we employed HEPES buffer (pH 7.5) and sodium phosphate buffer (pH 7.5) to prepare VAL from HPV using HpvZ. However, HPV was converted to unknown products in HEPES buffer, and the reaction product was not detected in sodium phosphate buffer (data not shown). In addition, HPV conversion rate was significantly decreased in HEPES buffer (approximately 60%) and sodium phosphate buffer (approximately 50%). Therefore, we examined the ability of these 21 ALDHs to convert VAL by measuring the amount of VAA produced from HPV when HPV was reacted with both HpvZ and each ALDH. Resting cells of *E. coli* expressing each ALDH gene and *hvpZ*-expressing *E. coli* were mixed and incubated with 100 μ M HPV for 12 h. When resting cells of *E. coli* harboring a vector and the *hvpZ*-expressing *E. coli* were incubated with HPV, VAA was not generated, while VAL-Tris accumulated. On the other hand, when *E. coli* cells carrying each of the 13 ALDH genes [SLG_07270, SLG_07610, SLG_07790, SLG_09510, SLG_11410, SLG_12800, SLG_18210, SLG_20400, SLG_27910 (*bzaA*), SLG_27920 (*bzaB*), SLG_28150, SLG_31150, SLG_38120] were used instead of the control vector, HPV was converted into VAA (Fig. 5A). Of the 13 ALDH genes, when incubating with *E. coli* carrying SLG_07270, SLG_12800, SLG_18210, SLG_20400, *bzaA*, *bzaB*, and SLG_31150, larger amounts of VAA accumulated (Fig. 5A). We, therefore, measured the VAA production time course using *E. coli* carrying these 7 ALDH genes and the *hvpZ*-expressing *E. coli*. Of these, *E. coli* carrying SLG_07270, SLG_12800, SLG_20400, and *bzaB* produced a greater amount of VAA than *E. coli* carrying one of the 3 other ALDH genes (Fig. 5B). Specifically, when using *E. coli* carrying SLG_20400, the

amount of VAA produced was the greatest, and no VAL-Tris was detected at any of the sampling points (Fig. 5B).

In order to examine whether SLG_07270, SLG_12800, SLG_20400, and *bzaB* are involved in the conversion of VAL in SYK-6, SLG_07270 mutant (SME092) and SLG_20400 mutant (SME061) were created (Fig. S3C–F). Resting cells of SME092, SME061, and the previously created SLG_12800 mutant (SME031) and *bzaB* mutant (SME045) were incubated with 1 mM HPV in the presence of *hpvZ*-expressing *E. coli* cells. SME061 accumulated a 1.8-fold greater amount of VAL-Tris than the wild type or the other mutants after 20 h incubation (Fig. 5C). These results suggested that SLG_20400 is involved in VAL oxidation. However, SME061 accumulated only 75 μ M VAL-Tris at 20 h of incubation. Therefore, multiple ALDHs including SLG_20400 appear to be involved in the conversion of VAL. Our previous phylogenetic analysis of the 23 ALDH genes in SYK-6 and other known ALDH genes indicated that 13 SYK-6 ALDH genes, the products of which showed VAL oxidation activities, are phylogenetically diverse (51). SLG_20400 clustered with *calB*, which encodes coniferyl aldehyde dehydrogenase from *Pseudomonas* sp. strain HR199, which shared 33% amino acid sequence identity with SLG_20400 (51, 52). Involvement of multiple ALDH genes in SYK-6 was also shown in the oxidation of vanillin, syringaldehyde, and an intermediate metabolite of DCA (DCA-L) (50, 51). Another example of the involvement of multiple ALDH genes in the conversion of vanillin has also been reported for *P. putida* KT2440 (53). Since ALDHs exhibit broad substrate ranges in general, multiple ALDHs are likely to play roles in the oxidation of aromatic aldehydes to their acids.

Candidate genes for the catabolism of VAA. In a previous report, Palamuru et

al. detected vanillin as a metabolite when SYK-6 cells were incubated with GGE (24). However, vanillin was not observed during the conversion of HPV (Fig. 2). In order to examine whether vanillin is an actual intermediate in HPV catabolism, resting cells of a *desV ligV* double mutant (SME077), which has a weak ability to convert vanillin (51), were incubated with 100 μ M VAA or ferulate. Only the accumulation of vanillate and acetovanillone was observed at any of the sampling points (1, 2, 4, 6, and 24 h) in the mixture for the VAA conversion, whereas the mixture for the ferulate conversion accumulated a significant amount of vanillin in addition to vanillate (Fig. 6; chromatograms at 2 and 4 h of incubation are shown). In addition, when a cell extract (>10 kDa) of SME077 was incubated with 100 μ M VAA in the presence of CoA, MgSO₄, and ATP, only the accumulation of vanillate and acetovanillone was observed (Fig. S8). These results suggested that VAA was catabolized to vanillate without passing through vanillin as an intermediate.

We hypothesized that the feruloyl-CoA synthetase gene (*ferA*) and feruloyl-CoA hydratase/lyase genes (*ferB* and *ferB2*) may be involved in VAA catabolism based on the structural similarity between VAA and ferulic acid (36). These genes were adequately expressed in *E. coli* (Fig. S9). When crude FerA was incubated with 100 μ M VAA in the presence of CoA, MgSO₄, and ATP for 60 min, compound IX with a retention time of 1.7 min was generated (Fig. S10B). Negative ESI-MS analysis of compound IX showed fragments at m/z 959 ($[M - H]^-$) and 479 ($[M - 2H]^{2-}$), suggesting that compound IX was the CoA derivative of VAA (VAA-CoA; Mw, 960) (Fig. S10E). However, no other peak except VAA-CoA was observed when crude enzymes of FerA + FerB and FerA + FerB2 were incubated with VAA, respectively (Fig. S10C and D). Therefore, FerB and FerB2 appear to be not involved in the conversion of VAA-CoA.

In order to examine whether *ferA* is indeed involved in the conversion of VAA in SYK-6, resting cells of a previously created *ferA* mutant (SME009) grown in LB were incubated with 100 μ M VAA. SME009 showed a higher conversion rate for VAA than that of the wild type (Fig. S11), suggesting that *ferA* is not essential for the catabolism of VAA. The reason for the high conversion rate of VAA of SME009 is not clear but disruption of *ferA* may cancel the substrate competition between FerA and (an) unidentified true VAA-converting enzyme(s).

Recently, the catabolic pathway of *p*-hydroxycinnamate derivatives, such as dihydroferulate, ferulate, and *p*-coumarate in *Rhodococcus jostii* RHA1, were characterized (37). In this pathway, dihydroferulate was catabolized to vanillate via VAA-CoA. VAA-CoA was converted into vanillate and acetyl-CoA by the gene product of *couO* (ro0512), which encodes 4-hydroxyphenoxy- β -ketoacyl-CoA hydrolase. CouO was predicted to be a zinc-dependent metalloenzyme belonging to amidohydrolase superfamily. Orthologs of *couO*, showing 53%–58% amino acid sequence identity, have also been found and characterized in *Agrobacterium fabrum* C58 (Atu1421) (38) and *Corynebacterium glutamicum* (*phdC*) (39). In the SYK-6 genome, we found SLG_12680, which exhibited 50% amino acid sequence identity with CouO. We are currently investigating the function of the gene product of SLG_12680 and exploring the actual gene encoding CoA ligase for VAA.

Genome search for orthologs of *hvpZ* in other bacteria. Since HvpZ is essential for the catabolism of HPV and HPS, the presence of this gene determines whether bacteria can utilize the A-ring portion of β -aryl ether compounds. BLAST searches of *hvpZ* were carried out to determine the distribution of its orthologs among bacteria. The

$hvpZ$ orthologs that showed high amino acid sequence identity (62%–92%) were found in *Altererythrobacter* sp. strain Root672 (ASD76_15935), *Altererythrobacter atlanticus* (WYH_02786), *Erythrobacter* sp. strain SG61-1L (SZ64_15220), *Sphingomonas hengshuiensis* WHSC-8 (TS85_07880), and *Sphingobium* sp. strain 66-54 (BGP16_16810). All these bacteria possess orthologs of the genes responsible for the conversion of GGE into HPV. Among these strains, SG61-1L was reported to be able to utilize GGE as the sole source of carbon and energy (24). By contrast, *Novosphingobium* sp. strain MBES04 accumulated HPV from GGE (23). Consistent with this observation, MBES04 possesses GMC oxidoreductase family enzyme genes, whose products showed less than 37% amino acid sequence identity with HpvZ. Similarly, no $hvpZ$ orthologs were found in *Novosphingobium* sp. strain PP1Y and *Novosphingobium aromaticivorans* DSM 12444, which possess orthologs of the genes responsible for converting GGE into HPV. Due to the lack of $hvpZ$, PP1Y and DSM 12444 also appear to be able to utilize only the portion of the B-ring of β -aryl ether compounds as carbon and energy sources.

MATERIALS AND METHODS

Bacterial strains, plasmids, and culture conditions. The strains and plasmids used in this study are listed in Table 2. *Sphingobium* sp. strain SYK-6 and its mutants were grown in LB, Wx-SEMP, and Wx-SEMP containing 5 mM GGE at 30°C. *S. sanguinis* IAM 12578 was grown in LB at 30°C. When necessary, 50 mg kanamycin/liter, 100 mg streptomycin/liter, or 300 mg carbenicillin/liter were added to the cultures. *E. coli* strains were grown in LB at 37°C. For cultures of cells carrying

antibiotic resistance markers, the media for *E. coli* transformants were supplemented with 100 mg ampicillin/liter, 25 mg kanamycin/liter, or 12.5 mg chloramphenicol/liter.

Synthesis of HPS (S-Hibbert-Westwood-Lancefield ketone; Fig. 7)

Synthesis of 4-((tert-butyldimethylsilyl)oxy)-3,5-dimethoxybenzaldehyde (A) To a stirring solution of syringaldehyde (20.0 g, 109.8 mmol, 1.0 eq) in dichloromethane (DCM) (600 ml, $c = 0.18$ M) was added 4-dimethylaminopyridine (4-DMAP) (13.4 g, 109.8 mmol, 1.0 eq), and imidazole (Imid) (14.9 g, 219.6, 2.0 eq). The resulting mixture was allowed to stir for 5 min, and then butyldimethylchlorosilane (TBSCl) (17.3 g, 115.3 mmol, 1.1 eq) was added. The mixture was stirred at room temperature for 1 h. After the reaction had reached completion, it was neutralized with a saturated aqueous solution of NH_4Cl (2×300 ml). The organic layer was further washed with water (500 ml), brine (300 ml), dried with MgSO_4 , filtered, and concentrated in vacuo. Purification by silica gel chromatography using 5–10% ethyl acetate (EtOAc) in petroleum ether afforded compound A as a white solid (26.6 g, 89.8 mmol, 82%). Analytical data for compound A agreed with that previously reported in the reference (54). ^1H NMR (500 MHz, CDCl_3) δ 9.79 (s, 1H), 7.07 (s, 2H), 3.84 (s, 6 H), 0.98 (s, 9H), 0.13 (s, 6H); ^{13}C NMR (125 MHz, CDCl_3) δ 191.1, 152.0, 140.7, 129.4, 106.7, 55.8, 25.8, 18.9, -4.46.

Synthesis of Ethyl 3-(4-((tert-butyldimethylsilyl)oxy)-3,5-dimethoxyphenyl)-3-hydroxypropanoate (B) ethyl acetate (4.2 g, 47.5 mmol, 1.3 eq) was added to a cooled solution of lithium bis(trimethylsilyl)amide (LiHMDS) [1.0 M in tetrahydrofuran (THF); 47.5 ml, 47.5 mmol, 1.3 eq] in THF (100 ml) at -78°C . After 15 min, a solution of compound A (10.8 g, 36.6 mmol, 1.0 eq) in THF (20 ml, overall $c = 0.30$ M) was added at -78°C and the resulting mixture was left to stir at this temperature for 1 h. After

the reaction had reached completion, it was quenched with saturated aqueous solution of NH_4Cl (2×300 ml) and extracted with ethyl acetate (500 ml). The organic layer was further washed with water (500 ml), brine (300 ml), dried with MgSO_4 , filtered and concentrated in vacuo. Purification by silica gel chromatography using 10–20% ethyl acetate in petroleum ether afforded compound B as a light-yellow solid (12.5 g, 32.7 mmol, 89%). ^1H NMR (500 MHz, CDCl_3) δ 6.51 (s, 2H), 5.00 (dt, $J = 9.0, 3.5$ Hz, 1H), 4.13 (q, $J = 7.0$ Hz, 2H), 3.74 (s, 6H), 3.36 (m, 1H), 2.70 (dd, $J = 16.0, 9.0$ Hz, 1H), 2.63 (dd, $J = 16.0, 3.5$ Hz, 1H), 1.22 (t, $J = 7.0$ Hz, 3H), 0.97 (s, 9H), 0.08 (s, 6H); ^{13}C NMR (125 MHz, CDCl_3) δ 172.4, 151.5, 135.2, 133.6, 102.5, 70.6, 60.8, 55.7, 43.7, 25.8, 18.7, 14.2, -4.7.

Synthesis of 1-(4-((tert-butyldimethylsilyl)oxy)-3,5-dimethoxyphenyl)propane-

1,3-diol (C) A suspension of LiAlH_4 (1.4 g, 37.8 mmol, 2.2 eq) in THF (100 ml) was cooled to -20°C . After 15 min, a solution of compound B (6.6 g, 17.2 mmol, 1.0 eq) in THF (20 ml, overall $c = 0.14$ M) was added at -20°C and the resulting mixture was left to stir at this temperature for 1 h. After the reaction had reached completion, it was poured slowly into a stirring mixture of ethyl acetate (300 ml) and saturated aqueous solution of $\text{Na}_2\text{S}_2\text{O}_3$ (2×300 ml). The organic layer was washed brine (300 ml), dried with MgSO_4 , filtered and concentrated in vacuo. Purification by silica gel chromatography using 5–10% methanol in DCM afforded compound C as colorless oil (5.62 g, 16.4 mmol, 96%). ^1H NMR (500 MHz, CDCl_3) δ 6.49 (s, 2H), 4.79 (dd, $J = 8.5, 3.5$, 1H), 3.77 (m, 2H), 3.75 (s, 6H), 3.32 (s, 1H), 2.93 (s, 1H), 1.94 (dddd, $J = 14.0, 8.5, 7.0, 5.0$ Hz, 1H), 1.84 (ddt, $J = 14.0, 5.5, 4.0$ Hz, 1H), 0.98 (s, 9H), 0.09 (s, 6H); ^{13}C NMR (125 MHz, CDCl_3) δ 151.6, 137.2, 133.5, 102.6, 74.6, 61.5, 55.8, 40.6, 25.9, 18.8, -4.6.

Synthesis of 1-(4-((tert-butyldimethylsilyl)oxy)-3,5-dimethoxyphenyl)-3-

hydroxypropan-1-one (D) 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) (4.1 g, 18.1 mmol, 1.05 eq) was added to a stirring solution of compound C (5.6 g, 16.4 mmol, 1.0 eq) in THF (160 ml, $c = 0.10$ M) at 22°C and the resulting mixture was left to stir at this temperature for 12 h. Afterwards, the reaction mixture was diluted with ethyl acetate (300 ml) and washed with saturated aqueous solution of Na₂S₂O₃ (2 × 300 ml). The organic layer was washed water (300 ml), brine (300 ml), dried with MgSO₄, filtered and concentrated in vacuo. Purification by silica gel chromatography using 2–5% methanol in DCM afforded compound D as a white solid (5.1 g, 14.9 mmol, 91%). ¹H NMR (500 MHz, CDCl₃) δ 7.16 (s, 2H), 3.97 (app q, $J = 5.5$ Hz, 2H), 3.80 (s, 6H), 3.15 (t, $J = 5.5$ Hz, 2H), 3.01 (app t, $J = 6.0$ Hz, 1H), 0.97 (s, 9H), 0.11 (s, 6H); ¹³C NMR (125 MHz, CDCl₃) δ 199.1, 151.4, 139.9, 129.4, 105.6, 58.3, 55.8, 40.0, 25.7, 18.8, - 4.6.

Synthesis of HPS Tetrabutylammonium fluoride (TBAF) (1.0 M in THF, 8.8 ml,

8.8 mmol, 3.0 eq) was added to a stirring solution of compound D (1.0 g, 2.9 mmol, 1.0 eq) in THF (15 ml, $c = 0.20$ M) at 22°C and the resulting mixture was left to stir at this temperature for 1 h. Afterwards, the reaction mixture was diluted with ethyl acetate (300 ml) and washed with saturated aqueous solution of NH₄Cl (2 × 300 ml). The organic layer was washed water (300 ml), brine (300 ml), dried with MgSO₄, filtered and concentrated in vacuo. The crude material was recrystallized in petroleum ether and washed with a minimum amount of ethyl acetate to afford compound HPS as a white solid (0.5 g, 2.3 mmol, 77%). Spectroscopic data agreed with that previously reported in the reference (30). High-resolution MS $[M - H]^+$ calcd. For C₁₁H₁₃O₅ 225.0800; found 225.0766; ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.34 (s, 1H), 7.24 (s, 2H), 4.59 (s, 1H),

3.83 (s, 6H), 3.77 (t, $J = 6.5$ Hz, 2H), 3.10 (t, $J = 6.5$ Hz, 2H); ^{13}C NMR (125 MHz, DMSO- d_6) δ 197.4, 147.6, 140.8, 127.5, 106.0, 57.3, 56.1, 41.0.

Synthesis of HPV (G-Hibbert-Westwood-Lancefield ketone; Fig. 7)

Synthesis of 4-((tert-butyldimethylsilyl)oxy)-3-methoxybenzaldehyde (E)

Compound E was synthesized following the same experimental procedure as described for the synthesis of compound A. To vanillin (19.2 g, 126.0 mmol, 1.0 eq) in DCM (500 ml, $c = 0.25$ M) was added 4-DMAP (15.4 g, 126.0 mmol, 1.0 eq), imidazole (17.1 g, 252.0 mmol, 2.0 eq), and TBSCl (1.2 eq). Purification by silica gel chromatography using 5–10% ethyl acetate in petroleum ether afforded compound E as colorless oil (30.0 g, 113.1 mmol, 90%). Spectroscopic data was in agreement with the reference (55). ^1H NMR (400 MHz, CDCl_3) δ 9.73 (s, 1H), 7.27 (m, 2H), 6.85 (d, $J = 8.0$ Hz, 1H), 3.74 (s, 3H), 0.90 (s, 9H), 0.09 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 190.5, 151.4, 151.0, 130.9, 125.8, 120.5, 110.0, 55.1, 25.4, 18.3, -4.78.

Synthesis of Ethyl 3-(4-((tert-butyldimethylsilyl)oxy)-3-methoxyphenyl)-3-

hydroxypropanoate (F) Compound F was synthesized following the same experimental procedure as described for the synthesis of compound B. Compound E (10.9 g, 41.0 mmol, 1.0 eq) in THF (140 ml, $c = 0.29$ M). LiHMDS (1.0 M in THF; 53.2 ml, 53.2 mmol, 1.3 eq). ethyl acetate (4.7 g, 53.2, 1.3 eq). Purification by silica gel chromatography using 10–30% ethyl acetate in petroleum ether afforded compound F as light-yellow oil (11.9 g, 33.6 mmol, 81%). ^1H NMR (500 MHz, CDCl_3) δ 6.84 (d, $J = 1.5$ Hz, 1H), 6.72 (m, 2H), 4.98 (dt, $J = 5.0, 3.5$ Hz, 1H), 4.09 (q, $J = 7.0$ Hz, 2H), 3.73 (s, 3H), 3.50 (m, 1H), 2.68 (dd, $J = 16.0, 9.5$ Hz, 1H), 2.59 (dd, $J = 16.0, 4.0$ Hz, 1H), 1.18 (t, $J = 7.0$ Hz, 3H), 0.95 (s, 9H), 0.09 (s, 6H); ^{13}C NMR (125 MHz, CDCl_3) δ 172.3, 150.9, 144.4, 136.3, 120.6, 118.0, 109.5, 70.2, 60.7, 55.3, 43.6, 25.7, 18.4, 14.1, -

4.7.

Synthesis of 1-(4-((tert-butyldimethylsilyl)oxy)-3-methoxyphenyl)propane-1,3-

diol (G) Compound G was synthesized following the same experimental procedure as described for the synthesis of compound C. LiAlH₄ (1.6 g, 40.1 mmol, 2.2 eq) in THF (80 ml). Compound F (6.6 g, 18.6 mmol, 1.0 eq) in THF (20 ml, overall *c* = 0.18 M). Purification by silica gel chromatography using 5–10% methanol in DCM afforded compound G as light-yellow oil (5.4 g, 17.4 mmol, 94%). ¹H NMR (500 MHz, CDCl₃) δ 6.89 (d, *J* = 1.5 Hz, 1H), 6.80 (m, 2H), 4.86 (m, 1H), 3.81 (s, 3H), 3.23 (s, 1H), 2.88 (s, 1H), 2.00 (m, 1H), 1.88 (m, 1H), 1.01 (s, 9H), 0.16 (s, 6H); ¹³C NMR (125 MHz, CDCl₃) δ 151.0, 144.4, 138.1, 120.8, 118.1, 109.6, 74.3, 61.5, 55.6, 40.6, 25.8, 18.6, -4.5.

Synthesis of 1-(4-((tert-butyldimethylsilyl)oxy)-3-methoxyphenyl)-3-

hydroxypropan-1-one (H) Compound H was synthesized following the same experimental procedure as described for the synthesis of compound D. DDQ (4.3 g, 19.2 mmol, 1.05 eq). Compound G (5.4 g, 17.4 mmol, 1.0 eq) in THF (170 ml, *c* = 0.10 M). Purification by silica gel chromatography using 2–5% methanol in DCM afforded compound H as light-yellow oil (4.1 g, 13.3 mmol, 76%). ¹H NMR (400 MHz, CDCl₃) δ 7.43–7.35 (m, 2H), 6.82 (d, *J* = 8.0 Hz, 1H), 3.95 (t, *J* = 5.5 Hz, 2H), 3.79 (s, 3H), 3.12 (t, *J* = 5.5 Hz, 2H), 0.94 (s, 9H), 0.13 (s, 6H); ¹³C NMR (125 MHz, CDCl₃) δ 199.1, 151.1, 150.4, 130.8, 122.7, 120.3, 110.9, 58.2, 55.4, 40.0, 25.6, 18.5, -4.6.

Synthesis of HPV HPV was synthesized following the same experimental

procedure as described for the synthesis of HPS. TBAF (1.0 M in THF; 15.6 ml, 15.6 mmol, 1.2 eq). Compound H (4.13 g, 13.3 mmol, 1.0 eq) in THF (100 ml, *c* = 0.13 M). Purification by silica gel chromatography afforded HPV as a white solid (1.0 g, 5.1

mmol, 38%). Spectroscopic analysis was in agreement with the reference (30). High-resolution MS $[M + Na]^+$ calcd. For $C_{10}H_{12}O_4Na$ 196.0700; found 219.0625; 1H NMR (500 MHz, $CDCl_3$) δ 7.58-7.50 (m, 2H), 6.95 (d, $J = 8.0$ Hz, 1H), 6.12 (s, 1H), 4.01 (q, $J = 5.0$ Hz, 2H), 3.95 (s, 3H), 3.18 (t, $J = 5.0$ Hz, 2H), 2.73 (app t, $J = 5.9$ Hz, 1H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 199.2, 151.0, 146.9, 129.7, 123.8, 114.1, 109.7, 58.5, 56.2, 39.9.

Preparation of other substrates. MPHPV, DCA, and DCA-C were prepared as described previously (50, 56). For preparation of VAA, HPV was added into 15 ml of the cell suspensions of *hpvZ*-expressing *E. coli* cells (OD_{600} of 10.0) and SLG_20400-expressing *E. coli* cells (OD_{600} of 2.0) to a final concentration of 200 μ M. After incubation with shaking for 12 h at 30°C, the culture was centrifuged, and the supernatant was filtered using an Amicon ultra spin filter unit (3-kDa cutoff, Millipore). The resulting filtrate was used as a preparation of 200 μ M VAA. For preparation of VAL-Tris, HPV was added into 15 ml of the cell suspension of *S. sanguinis* IAM 12578 harboring pJB12830 cells (OD_{600} of 1.0) to a final concentration of 1 mM. After incubation with shaking for 45 h at 30°C, the culture was centrifuged, and the supernatant was collected. The supernatant was extracted with ethyl acetate, and then the extract was finally dissolved in the dimethyl sulfoxide. The compounds obtained were analyzed by HPLC-MS.

Other aromatic compounds were purchased from Tokyo Chemical Ind., Co., Ltd., Sigma-Aldrich Co., LLC, and Wako Pure Chemical Ind., Ltd.

Preparation of resting cells and cell extracts, and fractionation of cell

extracts. Cells of SYK-6 and its mutants grown in Wx-SEMP for 16 h or LB for 24 h were collected by centrifugation ($5,000 \times g$ for 5 min), and then washed twice with 50 mM Tris-HCl buffer (pH 7.5; buffer A). The cells were resuspended in the same buffer and used as resting cells. Cells were broken by an ultrasonic disintegrator (57), and the supernatants of cell lysates were obtained as cell extracts after centrifugation ($19,000 \times g$ for 15 min). To examine the cofactor requirements, cell extracts were filtered using an Amicon ultra spin filter unit (10 kDa cutoff, Millipore) and then washed 5 times with buffer A. The filtrates were used as cell extracts (>10 kDa). For fractionation of cell extracts, they were further centrifuged at $124,000 \times g$ for 30 min at 4°C , and the resulting supernatants were used as the soluble fraction. The pellets were washed twice with buffer A, resuspended in the same buffer, and used as the membrane fraction.

Identification of the metabolites. SYK-6 resting cells (OD_{600} of 5.0) were

incubated with 1 mM HPV or HPS in buffer A at 30°C with shaking. SME077 resting cells (OD_{600} of 0.5 or 5.0) were incubated with 100 μM VAA or 1 mM ferulic acid in buffer A at 30°C with shaking. Following incubation, portions of the reaction mixtures were collected, and reactions were stopped by centrifugation. Methanol was added to the resulting supernatants (final concentration, 40%), and the filtrated samples were analyzed by HPLC-MS.

SYK-6 cell extracts (>10 kDa; 500 μg protein/ml) were incubated with 200 μM HPV or HPS in the presence and absence of 500 μM NAD^{+} or 500 μM NAD^{+} + 2 mM CoA + 2.5 mM MgSO_4 + 2.5 mM ATP in buffer A at 30°C . SME077 cell extracts (>10 kDa; 500 μg protein/ml) were incubated with 100 μM VAA in the presence of 1 mM

CoA + 1.25 mM MgSO₄ + 1.25 mM ATP in buffer A at 30°C. The reactions were stopped by the addition of methanol or acetonitrile (final concentration, 50%) at various sampling time points. Precipitated proteins were removed by centrifugation at 19,000 × g for 15 min. The resulting supernatants of the reaction mixtures were analyzed by HPLC-MS.

Enzyme assays using cell extracts of SYK-6. HPV-oxidizing activities of SYK-6 cell extracts were determined by measuring the decrease in the amount of HPV by HPLC analysis. In order to examine the effect of GGE on enzyme induction, SYK-6 cells grown in LB were inoculated into Wx-SEMP to an OD₆₀₀ of 0.2, and grown at 30°C. GGE (5 mM) was added when the OD₆₀₀ of the culture reached 0.5, and the culture was then further incubated for 12 h. SYK-6 cell extracts (500 µg protein/ml) were incubated with 200 µM HPV in the presence and absence of cofactors (500 µM PMS, 500 µM FAD + PMS, or 500 µM NAD⁺) in buffer A for 30 min at 30°C. The reaction mixtures were analyzed by HPLC, and HPV was detected at 276 nm. The specific activity was expressed in moles of HPV converted per min per milligram of protein.

In order to examine the activity of VAL-oxidizing activity, production of VAA from HPV was measured when HPV was reacted with SYK-6 cell extracts (>10 kDa). The cell extracts (>10 kDa; 500 µg protein/ml) were incubated with HPV in the presence of cofactors (500 µM FAD, 500 µM NAD⁺, or 500 µM NADP⁺) in buffer A for 2 h at 30°C. The supernatant of the reaction mixtures was analyzed by HPLC, and compounds were detected at 280 nm.

Analytical methods.

HPLC-MS analysis was performed with the ACQUITY UPLC system (Waters) coupled with an ACQUITY TQ detector as described previously (58). Reaction products of HPV, coniferyl alcohol, sinapyl alcohol, cinnamyl alcohol, 3-(4-hydroxyphenyl)-1-propanol, homovanillyl alcohol, vanillyl alcohol, GGE, MPHPV, DCA, and DCA-C were analyzed using TSKgel ODS-140HTP column (2.1×100 mm; Tosoh). Reaction products of HPS were analyzed using ACQUITY UPLC BEH C18 column (2.1×100 mm; Waters). Reaction products of VAA were analyzed using both columns. All analyses were carried out at a flow rate of 0.5 ml/min. The mobile phase was a mixture of solution A (acetonitrile containing 0.1% formate) and B (water containing 0.1% formate) with the following conditions: *Detection of the reaction products of HPV*: 0–4.2 min, 5% A; 4.2–6.0 min, linear gradient from 5% to 30% A; 6.0–6.5 min, decreasing gradient from 30% to 5% A; 6.5–7.0 min, 5% A. *Detection of VAL generated from HPV*: 0–4.7 min, 5% A; 4.7–4.9 min, linear gradient from 5% to 80%; 4.9–7.0 min, 80% A. *Detection of VAA-CoA generated from VAA*: 0–0.8 min, 10% A; 0.8–1.0 min, linear gradient from 10% to 25% A; 1.0–1.5 min, 25% A; 1.5–1.8 min, decreasing gradient from 25% to 10% A; 1.8–3.0 min, 10% A. *Detection of vanillate generated from VAA*: 0–3.0 min, linear gradient from 5% to 15% A; 3.0–4.0 min, decreasing gradient from 15% to 5%. *Detection of the reaction product of vanillyl alcohol*: 0–5.0 min, 5% A. *Detection of the reaction products of coniferyl alcohol, sinapyl alcohol, cinnamyl alcohol, homovanillyl alcohol, and HPS*: 0–7.0 min, 10% A. *Detection of the reaction products of 3-(4-hydroxyphenyl)-1-propanol, GGE, and ferulate*: 0–5.0 min, 15% A. *Detection of the reaction products of MPHPV, DCA, and DCA-C*: 0–5.0 min, 25% A. HPV, HPS, VAL, VAL-Tris, VAA, VAA-CoA, vanillate, syringate, acetovanillone, coniferyl alcohol, sinapyl alcohol, cinnamyl alcohol, 3-(4-hydroxyphenyl)-1-propanol,

homovanillyl alcohol, vanillyl alcohol, GGE, MPPHV, DCA, and DCA-C were detected at 276, 300, 310, 352, 280, 300, 260, 276, 275, 263, 273, 250, 276, 279, 279, 277, 280, 277, and 326 nm, respectively. In ESI-MS analysis, MS spectra were obtained using the positive- and negative-ion modes with the settings described in our previous study (58). Protein concentrations were determined by the Bradford method using the Bio-Rad protein assay kit or by Lowry's assay using the DC protein assay kit (Bio-Rad Laboratories). The expression of the genes was analyzed by SDS-PAGE. Protein bands in gels were stained with Coomassie Brilliant Blue.

DNA manipulations and sequence analysis. PCR primers used in this study are listed in Table 3. Nucleotide sequences were determined using a CEQ 2000XL genetic analysis system (Beckman Coulter). Sequence analysis was performed with the MacVector program (MacVector, Inc.). Sequence similarity searches, pairwise alignments, and multiple alignments were carried out using the BLASTP program (59), the EMBOSS Needle program through the EMBL-EBI server (60), and the Clustal Omega program (61), respectively.

Cloning of *hvpZ*. A partially SalI-digested gene library of SYK-6 constructed with pVK100 was introduced into a host strain, *S. sanguinis* IAM 12578, by triparental mating (62). The ability of 1000 transconjugants grown in diluted LB to transform 15 μ M HPV was analyzed by HPLC. Southern hybridization analysis of the SalI digests of positive clones with pSA53 as a probe was carried out using the digoxigenin (DIG) system (Roche Diagnostics). The hybridized SalI fragments were cloned in pBluescript II SK(+), and the nucleotide sequences of both ends of the inserts were determined.

Expression of SYK-6 genes in *E. coli* and SYK-6. A DNA fragment carrying *hvpZ* was amplified by PCR using SYK-6 total DNA as a template. The amplified fragment was ligated into pT7Blue, and the NdeI-BamHI fragment of the resulting plasmid was then inserted in pCold I to generate pCold12830. DNA fragments carrying *ferB* and *ferB2* were amplified by PCR. The amplified fragments were ligated into pET-16b to obtain pE16FB and pE16FB2. Nucleotide sequences of their inserts were confirmed by nucleotide sequencing. Expression plasmids for SYK-6 ALDH genes and *ferA* were prepared in previous studies (31, 51). The expression plasmids were introduced into *E. coli* BL21(DE3), and the transformed cells were grown in LB. In the case of *hvpZ* expression, pTf16 encoding the trigger factor chaperone was introduced into *E. coli* BL21(DE3) in addition to pCold12830, and the resulting transformant was grown in the presence of 0.5 mg/ml L-arabinose. Expression of *hvpZ* and other genes were induced for 24 h at 16°C and for 4 h at 30°C, respectively, by adding 0.1–1 mM isopropyl-β-D-thiogalactopyranoside when the OD₆₀₀ of the cultures reached 0.5. Cells were then harvested by centrifugation and washed with buffer A. pJB12830 was created by inserting the 2.3-kb BamHI-SacII (blunted) fragment carrying *hvpZ* from pBH37F into pJB864. pJB12830 was introduced into SYK-6, and the transformed cells were grown in LB containing 1 mM *m*-toluate for 24 h. Resting cells and cell extracts were prepared as described above.

Construction of mutants. To construct pKmb12830K, the 1.3-kb SalI-BamHI fragment carrying the kanamycin resistance gene (*kan*) of pIK03 was inserted into the XhoI-BglII sites in *hvpZ* of pUC12830. The 3.1-kb SalI fragment of the resulting

plasmid was ligated into the same site of pK19*mobsacB* to obtain pKmb12830K. To construct pKmb07270K, the 1.5-kb HindIII-XbaI fragment of pKS0727 was ligated into the same sites of pK18*mobsacB*, yielding pKmb07270. pKmb07270K was constructed by inserting *kan* into the NruI site in SLG_07270 of pKmb07270. pKmb12830K and pKmb07270K were independently introduced into SYK-6 cells by electroporation, and candidate mutants were isolated as described previously (63). Disruption of each gene was examined by Southern hybridization analysis (Fig. S3). To construct pAK20400, upstream and downstream regions (ca. 1.0 kb each) of SLG_20400 were amplified by PCR. The resulting fragments were cloned into pAK405 by In-fusion cloning (In-Fusion HD Cloning Kit; Takara Bio). pAK20400 was introduced into SYK-6 cells by triparental mating (62), and the mutant strain was selected as described previously (64). Disruption of the gene was confirmed by colony PCR. For the complementation of *hvpZ* in SME059, pJB12830 was introduced into cells by electroporation.

Resting cell assays. Resting cells of *E. coli* harboring pCold12830 and pTf16 (OD₆₀₀ of 10.0), SYK-6 (OD₆₀₀ of 0.5, 1.0, or 5.0), SYK-6 harboring pJB864 (OD₆₀₀ of 1.0), SME059 (OD₆₀₀ of 0.5, 1.0, or 5.0), SME059 harboring pJB864 (OD₆₀₀ of 1.0), SME059 harboring pJB12830 (OD₆₀₀ of 1.0), and SME009 (OD₆₀₀ of 1.0) prepared from LB-grown cultures were incubated with substrates (200 μ M HPV, 200 μ M HPS, 200 μ M GGE, or 100 μ M VAA) at 30°C with shaking. Portions of the cultures were collected and the amounts of substrates were measured by HPLC.

Enzyme properties of HvpZ. To determine the cellular localization of HvpZ, the HPV-oxidizing activities of the soluble and membrane fractions prepared from cell

extracts of SYK-6 were measured. The cell extracts (500 µg of protein/ml), soluble fraction (500 µg mg of protein/ml), and membrane fraction (500 µg of protein/ml) were incubated with 200 µM HPV and 500 µM PMS in buffer A for 10 or 30 min at 30°C. The amounts of HPV were measured by HPLC.

The enzyme reaction was typically carried out by incubating the membrane fraction (300 µg of protein/ml) of *E. coli* cells harboring pCold12830 and pTf16 with 200 µM HPV and 500 µM PMS in buffer A for 10 min at 30°C. Following incubation, the amount of substrate was measured by HPLC. The optimum pH was determined at pH ranges from 7.0 to 10.0 using 50 mM GTA buffer (50 mM 3,3-dimethylglutaric acid, 50 mM Tris, and 50 mM 2-amino-2-methyl-1,3-propanediol; pH 7.0 to 9.0) and 50 mM CHES (*N*-cyclohexyl-2-aminoethanesulfonic acid) buffer (pH 8.6 to 10) at 30°C. The optimum temperature was determined at temperature ranges from 25°C to 50°C using buffer A. To determine the substrate range, 200 µM of HPV, HPS, coniferyl alcohol, sinapyl alcohol, cinnamyl alcohol, 3-(4-hydroxyphenyl)-1-propanol, homovanillyl alcohol, vanillyl alcohol, GGE, MPHPV, DCA, and DCA-C were used for the reaction, and the decrease in the amount of substrate was measured by HPLC. To examine the effect of flavin cofactors on HpvZ activity, the activities of HpvZ in the presence of 500 µM FAD or flavin mononucleotide were determined. To examine the effect of ubiquinone derivatives on HpvZ activity, the activities of HpvZ in the presence of CoQ₀ and CoQ₁ were determined. The enzyme reactions were carried out by incubating membrane fractions of *E. coli* cells harboring pCold12830 and pTf16 (300 µg of protein/ml) or SYK-6 cells harboring pJB12830 (300 µg of protein/ml) with 200 µM HPV and 500 µM CoQ₀ or CoQ₁ in buffer A for 10 and 5 min, respectively, at 30°C. The decrease in the substrate was determined by HPLC analysis.

Identification of the ALDH genes involved in VAL conversion. The abilities of the 23 ALDHs of SYK-6 to convert VAL were examined by measuring the amount of VAA produced from HPV when HPV was reacted with both HpvZ and each ALDH. Resting cells of *E. coli* expressing each ALDH gene (OD₆₀₀ of 1.0) and *E. coli* harboring pCold12830 and pTf16 (OD₆₀₀ of 5.0 or 10.0) were incubated with 100 μM HPV in buffer A at 30°C with shaking. Portions of the cultures were collected at various sampling time points, and the supernatants of the reaction mixtures were analyzed by HPLC.

The mixtures of resting cells of SYK-6, SME031, SME045, SME061, or SME092 (OD₆₀₀ of 0.5) and resting cells of *E. coli* harboring pCold12830 and pTf16 (OD₆₀₀ of 10.0) were incubated with 1 mM HPV in buffer A at 30°C with shaking. Portions of the reaction mixtures were collected at various sampling time points. The supernatants prepared were analyzed by HPLC.

Conversion of VAA by enzymes for ferulate catabolism. Crude enzymes of FerA, FerB, and FerB2 were prepared from the *E. coli* transformants described above. FerA, FerA + FerB, and FerA + FerB2 (100 μg protein/ml of each) were incubated with 100 μM VAA, 1 mM CoA, 1.25 mM MgSO₄, and 1.25 mM ATP in buffer A for 60 min at 30°C. The supernatants prepared were analyzed by HPLC.

ACKNOWLEDGMENTS

793 We thank Daisuke Sato for assistance with the construction of mutants. We would also
794 like to thank Daniel Miles-Barrett and Amol Thakkar for their contributions. This work
795 was supported in part by a grant from the JSPS KAKENHI Grant Number 26850046,
796 and the Japan Science and Technology Agency (Advanced Low Carbon Technology
797 Research and Development Program).

REFERENCES

1. **Boerjan W, Ralph J, Baucher M.** 2003. Lignin biosynthesis. *Annu Rev Plant Biol* **54**:519-546.
2. **Ralph J, Lundquist K, Brunow G, Lu F, Kim H, Schatz PF, Marita JM, Hatfield RD, Ralph SA, Christensen JH, Boerjan W.** 2004. Lignins: natural polymers from oxidative coupling of 4-hydroxyphenyl-propanoids. *Phytochem Rev* **3**:29-60.
3. **Doherty WOS, Mousavioun P, Fellows CM.** 2011. Value-adding to cellulosic ethanol: Lignin polymers. *Ind Crop prod* **33**:259-276.
4. **Zakzeski J, Bruijninx PCA, Jongerius AL, Weckhuysen BM.** 2010. The catalytic valorization of lignin for the production of renewable chemicals. *Chem Rev* **110**:3552-3599.
5. **Otsuka Y, Nakamura M, Shigehara K, Sugimura K, Masai E, Ohara S, Katayama Y.** 2006. Efficient production of 2-pyrone 4,6-dicarboxylic acid as a novel polymer-based material from protocatechuate by microbial function. *Appl Microbiol Biotechnol* **71**:608-614.
6. **Michinobu T, Bito M, Yamada Y, Tanimura M, Katayama Y, Masai E, Nakamura M, Otsuka Y, Ohara S, Shigehara K.** 2009. Fusible, elastic, and biodegradable polyesters of 2-pyrone-4,6-dicarboxylic acid (PDC). *Polym J* **41**:1111-1116.
7. **Michinobu T, Hiraki K, Inazawa Y, Katayama Y, Masai E, Nakamura M, Ohara S, Shigehara K.** 2011. Click synthesis and adhesive properties of novel biomass-based polymers from lignin-derived stable metabolic intermediate. *Polym J* **43**:648-653.
8. **Sonoki T, Morooka M, Sakamoto K, Otsuka Y, Nakamura M, Jellison J, Goodell B.** 2014. Enhancement of protocatechuate decarboxylase activity for the effective production of muconate from lignin-related aromatic compounds. *J Biotechnol* **192 Pt A**:71-77.
9. **Johnson CW, Salvachúa D, Khanna P, Smith H, Peterson DJ, Beckham GT.** 2016. Enhancing muconic acid production from glucose and lignin-derived aromatic compounds via increased protocatechuate decarboxylase activity. *Metab Eng Commun* **3**:111-119.
10. **Sonoki T, Takahashi K, Sugita H, Hatamura M, Azuma Y, Sato T, Suzuki S, Kamimura N, Masai E.** 2018. Glucose-free *cis*, *cis*-muconic acid production via new metabolic designs corresponding to the heterogeneity of lignin. *ACS Sustainable Chem Eng* **6**:1256-1264.

- 834 11. **Linger JG, Vardon DR, Guarnieri MT, Karp EM, Hunsinger GB, Franden**
835 **MA, Johnson CW, Chupka G, Strathmann TJ, Pienkos PT, Beckham GT.**
836 2014. Lignin valorization through integrated biological funneling and chemical
837 catalysis. *Proc Natl Acad Sci U S A* **111**:12013-12018.
- 838 12. **Akiyama T, Magara K, Matsumoto Y, Meshitsuka G, Ishizu A, Lundquist K.**
839 2000. Proof of the presence of racemic forms of arylglycerol- β -aryl ether structure
840 in lignin: studies on the stereo structure of lignin by ozonation. *J Wood Sci*
841 **46**:414-415.
- 842 13. **Kamimura N, Takahashi K, Mori K, Araki T, Fujita M, Higuchi Y, Masai E.**
843 2017. Bacterial catabolism of lignin-derived aromatics: New findings in a recent
844 decade: Update on bacterial lignin catabolism. *Environ Microbiol Rep* **9**:679-705.
- 845 14. **Sato Y, Moriuchi H, Hishiyama S, Otsuka Y, Oshima K, Kasai D, Nakamura**
846 **M, Ohara S, Katayama Y, Fukuda M, Masai E.** 2009. Identification of three
847 alcohol dehydrogenase genes involved in the stereospecific catabolism of
848 arylglycerol- β -aryl ether by *Sphingobium* sp. strain SYK-6. *Appl Environ*
849 *Microbiol* **75**:5195-5201.
- 850 15. **Masai E, Ichimura A, Sato Y, Miyauchi K, Katayama Y, Fukuda M.** 2003.
851 Roles of the enantioselective glutathione *S*-transferases in cleavage of β -aryl ether.
852 *J Bacteriol* **185**:1768-1775.
- 853 16. **Tanamura K, Abe T, Kamimura N, Kasai D, Hishiyama S, Otsuka Y,**
854 **Nakamura M, Kajita S, Katayama Y, Fukuda M, Masai E.** 2011.
855 Characterization of the third glutathione *S*-transferase gene involved in
856 enantioselective cleavage of the β -aryl ether by *Sphingobium* sp. strain SYK-6.
857 *Biosci Biotechnol Biochem* **75**:2404-2407.
- 858 17. **Meux E, Prosper P, Masai E, Mulliert G, Dumarçay S, Morel M, Didierjean**
859 **C, Gelhaye E, Favier F.** 2012. *Sphingobium* sp. SYK-6 LigG involved in lignin
860 degradation is structurally and biochemically related to the glutathione transferase
861 omega class. *FEBS Lett* **586**:3944-3950.
- 862 18. **Pereira JH, Heins RA, Gall DL, McAndrew RP, Deng K, Holland KC,**
863 **Donohue TJ, Noguera DR, Simmons BA, Sale KL, Ralph J, Adams PD.** 2016.
864 Structural and biochemical characterization of the early and late enzymes in the
865 lignin β -aryl ether cleavage pathway from *Sphingobium* sp. SYK-6. *J Biol Chem*
866 **291**:10228-10238.
- 867 19. **Reiter J, Strittmatter H, Wiemann LO, Schieder D, Sieber V.** 2013. Enzymatic
868 cleavage of lignin β -O-4 aryl ether bonds via net internal hydrogen transfer. *Green*
869 *Chem* **15**:1373-1381.

- 870 20. **Gall DL, Kim H, Lu F, Donohue TJ, Noguera DR, Ralph J.** 2014.
871 Stereochemical features of glutathione-dependent enzymes in the *Sphingobium* sp.
872 strain SYK-6 β -aryl etherase pathway. *J Biol Chem* **289**:8656-8667.
- 873 21. **Gall DL, Ralph J, Donohue TJ, Noguera DR.** 2014. A group of sequence-
874 related sphingomonad enzymes catalyzes cleavage of β -aryl ether linkages in
875 lignin β -guaiacyl and β -syringyl ether dimers. *Environ Sci Technol* **48**:12454-
876 12463.
- 877 22. **Picart P, Müller C, Mottweiler J, Wiermans L, Bolm C, Domínguez de María**
878 **P, Schallmey A.** 2014. From gene towards selective biomass valorization:
879 bacterial β -etherases with catalytic activity on lignin-like polymers.
880 *ChemSusChem* **7**:3164-3171.
- 881 23. **Ohta Y, Nishi S, Hasegawa R, Hatada Y.** 2015. Combination of six enzymes of
882 a marine *Novosphingobium* converts the stereoisomers of β -O-4 lignin model
883 dimers into the respective monomers. *Sci Rep* **5**:15105.
- 884 24. **Palamuru S, Dellas N, Pearce SL, Warden AC, Oakeshott JG, Pandey G.**
885 2015. Phylogenetic and kinetic characterization of a suite of dehydrogenases from
886 a newly isolated bacterium, strain SG61-1L, that catalyze the turnover of
887 guaiacylglycerol- β -guaiacyl ether stereoisomers. *Appl Environ Microbiol*
888 **81**:8164-8176.
- 889 25. **Picart P, Sevenich M, P DdM, Schallmey A.** 2015. Exploring glutathione lyases
890 as biocatalysts: paving the way for enzymatic lignin depolymerization and future
891 stereoselective applications. *Green Chem* **17**:4931-4940.
- 892 26. **Helmich KE, Pereira JH, Gall DL, Heins RA, McAndrew RP, Bingman C,**
893 **Deng K, Holland KC, Noguera DR, Simmons BA, Sale KL, Ralph J, Donohue**
894 **TJ, Adams PD, Phillips GN, Jr.** 2016. Structural basis of stereospecificity in the
895 bacterial enzymatic cleavage of β -aryl ether bonds in lignin. *J Biol Chem*
896 **291**:5234-5246.
- 897 27. **Ohta Y, Hasegawa R, Kurosawa K, Maeda AH, Koizumi T, Nishimura H,**
898 **Okada H, Qu C, Saito K, Watanabe T, Hatada Y.** 2017. Enzymatic specific
899 production and chemical functionalization of phenylpropanone platform
900 monomers from lignin. *ChemSusChem* **10**:425-433.
- 901 28. **Rosini E, Allegretti C, Melis R, Cerioli L, Conti G, Pollegioni L, D'Arrigo P.**
902 2016. Cascade enzymatic cleavage of the β -O-4 linkage in a lignin model
903 compound. *Catal Sci Technol* **6**:2195-2205.
- 904 29. **Higuchi Y, Takahashi K, Kamimura N, Masai E.** 2018. Bacterial enzymes for
905 the cleavage of lignin β -aryl ether bonds: properties and applications. *In* Beckham

- 906 GT (ed), Lignin Valorization: Emerging Approaches. The Royal Society of
907 Chemistry (in press).
- 908 30. **Lancefield CS, Ojo OS, Tran F, Westwood NJ.** 2015. Isolation of functionalized
909 phenolic monomers through selective oxidation and C-O bond cleavage of the β -
910 O-4 linkages in lignin. *Angew Chem Int Ed Engl* **54**:258-262.
- 911 31. **Kasai D, Kamimura N, Tani K, Umeda S, Abe T, Fukuda M, Masai E.** 2012.
912 Characterization of FerC, a MarR-type transcriptional regulator, involved in
913 transcriptional regulation of the ferulate catabolic operon in *Sphingobium* sp.
914 strain SYK-6. *FEMS Microbiol Lett* **332**:68-75.
- 915 32. **Bubb WA, Berthon HA, Kuchel PW.** 1995. Tris buffer reactivity with low-
916 molecular-weight aldehydes - NMR characterization of the reactions of
917 glyceraldehyde-3-phosphate. *Bioorg Chem* **23**:119-130.
- 918 33. **Fukuzumi T, Oyake S, Matsumoto H.** 1974. Synthesis of vanilloyl acetaldehyde.
919 *Mokuzai Gakkaishi* **20**:138-142.
- 920 34. **Niwa M, Saburi Y.** 2002. Vanilloyl acetic acid as an unstable intermediate from
921 β -hydroxypropiovanillone to acetovanillone. *Holzforschung* **56**:360-362.
- 922 35. **Overhage J, Priefert H, Steinbüchel A.** 1999. Biochemical and genetic analyses
923 of ferulic acid catabolism in *Pseudomonas* sp. strain HR199. *Appl Environ*
924 *Microbiol* **65**:4837-4847.
- 925 36. **Masai E, Harada K, Peng X, Kitayama H, Katayama Y, Fukuda M.** 2002.
926 Cloning and characterization of the ferulic acid catabolic genes of *Sphingomonas*
927 *paucimobilis* SYK-6. *Appl Environ Microbiol* **68**:4416-4424.
- 928 37. **Otani H, Lee YE, Casabon I, Eltis LD.** 2014. Characterization of *p*-
929 hydroxycinnamate catabolism in a soil Actinobacterium. *J Bacteriol* **196**:4293-
930 4303.
- 931 38. **Campillo T, Renoud S, Kerzaon I, Vial L, Baude J, Gaillard V, Bellvert F,**
932 **Chamignon C, Comte G, Nesme X, Lavire C, Hommais F.** 2014. Analysis of
933 hydroxycinnamic acid degradation in *Agrobacterium fabrum* reveals a coenzyme
934 A-dependent, beta-oxidative deacetylation pathway. *Appl Environ Microbiol*
935 **80**:3341-3349.
- 936 39. **Kallscheuer N, Vogt M, Kappelmann J, Krumbach K, Noack S, Bott M,**
937 **Marienhagen J.** 2016. Identification of the *phd* gene cluster responsible for
938 phenylpropanoid utilization in *Corynebacterium glutamicum*. *Appl Microbiol*
939 *Biotechnol* **100**:1871-1881.
- 940 40. **Takahashi K, Hirose Y, Kamimura N, Hishiyama S, Hara H, Araki T, Kasai**
941 **D, Kajita S, Katayama Y, Fukuda M, Masai E.** 2015. Membrane-associated

- 942 glucose-methanol-choline oxidoreductase family enzymes PhcC and PhcD are
 943 essential for enantioselective catabolism of dehydrodiconiferyl alcohol. Appl
 944 Environ Microbiol **81**:8022-8036.
- 945 41. **Kirmair L, Skerra A.** 2014. Biochemical analysis of recombinant AlkJ from
 946 *Pseudomonas putida* reveals a membrane-associated, flavin adenine dinucleotide-
 947 dependent dehydrogenase suitable for the biosynthetic production of aliphatic
 948 aldehydes. Appl Environ Microbiol **80**:2468-2477.
- 949 42. **Ohta T, Kawabata T, Nishikawa K, Tani A, Kimbara K, Kawai F.** 2006.
 950 Analysis of amino acid residues involved in catalysis of polyethylene glycol
 951 dehydrogenase from *Sphingopyxis terrae*, using three-dimensional molecular
 952 modeling-based kinetic characterization of mutants. Appl Environ Microbiol
 953 **72**:4388-4396.
- 954 43. **Kawai F, Kimura T, Fukaya M, Tani Y, Ogata K, Ueno T, Fukami H.** 1978.
 955 Bacterial oxidation of polyethylene glycol. Appl Environ Microbiol **35**:679-684.
- 956 44. **Matsushita K, Ameyama M.** 1982. D-glucose dehydrogenase from
 957 *Pseudomonas fluorescens*, membrane-bound. Methods Enzymol **89**:149-154.
- 958 45. **Romero E, Gadda G.** 2014. Alcohol oxidation by flavoenzymes. Biomol
 959 Concepts **5**:299-318.
- 960 46. **Guillén F, Martínez AT, Martínez MJ.** 1992. Substrate specificity and
 961 properties of the aryl-alcohol oxidase from the ligninolytic fungus *Pleurotus*
 962 *eryngii*. Eur J Biochem **209**:603-611.
- 963 47. **Dijkman WP, de Gonzalo G, Mattevi A, Fraaije MW.** 2013. Flavoprotein
 964 oxidases: classification and applications. Appl Microbiol Biotechnol **97**:5177-
 965 5188.
- 966 48. **Quaye O, Lountos GT, Fan F, Orville AM, Gadda G.** 2008. Role of Glu312 in
 967 binding and positioning of the substrate for the hydride transfer reaction in choline
 968 oxidase. Biochemistry **47**:243-256.
- 969 49. **Tan TC, Spadiut O, Wongnate T, Sucharitakul J, Krondorfer I, Sygmund C,**
 970 **Haltrich D, Chaiyen P, Peterbauer CK, Divne C.** 2013. The 1.6 Å crystal
 971 structure of pyranose dehydrogenase from *Agaricus meleagris* rationalizes
 972 substrate specificity and reveals a flavin intermediate. PLoS One **8**:e53567.
- 973 50. **Takahashi K, Kamimura N, Hishiyama S, Hara H, Kasai D, Katayama Y,**
 974 **Fukuda M, Kajita S, Masai E.** 2014. Characterization of the catabolic pathway
 975 for a phenylcoumaran-type lignin-derived biaryl in *Sphingobium* sp. strain SYK-
 976 6. Biodegradation **25**:735-745.
- 977 51. **Kamimura N, Goto T, Takahashi K, Kasai D, Otsuka Y, Nakamura M,**

978 **Katayama Y, Fukuda M, Masai E.** 2017. A bacterial aromatic aldehyde
979 dehydrogenase critical for the efficient catabolism of syringaldehyde. *Sci Rep*
980 **7:44422.**

981 52. **Achterholt S, Priefert H, Steinbüchel A.** 1998. Purification and characterization
982 of the coniferyl aldehyde dehydrogenase from *Pseudomonas* sp. strain HR199 and
983 molecular characterization of the gene. *J Bacteriol* **180:4387-4391.**

984 53. **Simon O, Klaiber I, Huber A, Pfannstiel J.** 2014. Comprehensive proteome
985 analysis of the response of *Pseudomonas putida* KT2440 to the flavor compound
986 vanillin. *J Proteomics* **109:212-227.**

987 54. **Cushman M, Nagarathnam D, Gopal D, He HM, Lin CM, Hamel E.** 1992.
988 Synthesis and evaluation of analogues of (Z)-1-(4-methoxyphenyl)-2-(3,4,5-
989 trimethoxyphenyl)ethene as potential cytotoxic and antimitotic agents. *J Med*
990 *Chem* **35:2293-2306.**

991 55. **Shirai T, Kumihashi K, Sakasai M, Kusuoku H, Shibuya Y, Ohuchi A.** 2017.
992 Identification of a novel TRPM8 agonist from nutmeg: a promising cooling
993 compound. *ACS Med Chem Lett* **8:715-719.**

994 56. **Hishiyama S, Otsuka Y, Nakamura M, Ohara S, Kajita S, Masai E,**
995 **Katayama Y.** 2012. Convenient synthesis of chiral lignin model compounds via
996 optical resolution: four stereoisomers of guaiacylglycerol- β -guaiacyl ether and
997 both enantiomers of 3-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-2-(2-
998 methoxyphenoxy)-propan-1-one (erone). *Tetrahedron Lett* **53:842-845.**

999 57. **Fukuhara Y, Kamimura N, Nakajima M, Hishiyama S, Hara H, Kasai D,**
1000 **Tsuji Y, Narita-Yamada S, Nakamura S, Katano Y, Fujita N, Katayama Y,**
1001 **Fukuda M, Kajita S, Masai E.** 2013. Discovery of pinoresinol reductase genes
1002 in sphingomonads. *Enzyme Microb Technol* **52:38-43.**

1003 58. **Fukuhara Y, Inakazu K, Kodama N, Kamimura N, Kasai D, Katayama Y,**
1004 **Fukuda M, Masai E.** 2010. Characterization of the isophthalate degradation
1005 genes of *Comamonas* sp. strain E6. *Appl Environ Microbiol* **76:519-527.**

1006 59. **Johnson M, Zaretskaya I, Raytselis Y, Merezuk Y, McGinnis S, Madden TL.**
1007 2008. NCBI BLAST: a better web interface. *Nucleic Acids Res* **36:W5-9.**

1008 60. **Li W, Cowley A, Uludag M, Gur T, McWilliam H, Squizzato S, Park YM,**
1009 **Buso N, Lopez R.** 2015. The EMBL-EBI bioinformatics web and programmatic
1010 tools framework. *Nucleic Acids Res* **43:W580-584.**

1011 61. **Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, Lopez R,**
1012 **McWilliam H, Remmert M, Söding J, Thompson JD, Higgins DG.** 2011. Fast,
1013 scalable generation of high-quality protein multiple sequence alignments using

1014 Clustal Omega. *Mol Syst Biol* **7**:539.

1015 62. **Ditta G, Stanfield S, Corbin D, Helinski DR.** 1980. Broad host range DNA
1016 cloning system for gram-negative bacteria: construction of a gene bank of
1017 *Rhizobium meliloti*. *Proc Natl Acad Sci U S A* **77**:7347-7351.

1018 63. **Masai E, Shinohara S, Hara H, Nishikawa S, Katayama Y, Fukuda M.** 1999.
1019 Genetic and biochemical characterization of a 2-pyrone-4,6-dicarboxylic acid
1020 hydrolase involved in the protocatechuate 4,5-cleavage pathway of *Sphingomonas*
1021 *paucimobilis* SYK-6. *J Bacteriol* **181**:55-62.

1022 64. **Kaczmarczyk A, Vorholt JA, Francez-Charlot A.** 2012. Markerless gene
1023 deletion system for sphingomonads. *Appl Environ Microbiol* **78**:3774-3777.

1024 65. **Katayama Y, Nishikawa S, Nakamura M, Yano K, Yamasaki M, Morohoshi**
1025 **N, Haraguchi T.** 1987. Cloning and expression of *Pseudomonas paucimobilis*
1026 SYK-6 genes involved in the degradation of vanillate and protocatechuate in *P.*
1027 *putida*. *Mokuzai Gakkaishi* **33**:77-79.

1028 66. **Peng X, Masai E, Kasai D, Miyauchi K, Katayama Y, Fukuda M.** 2005. A
1029 second 5-carboxyvanillate decarboxylase gene, *ligW2*, is important for lignin-
1030 related biphenyl catabolism in *Sphingomonas paucimobilis* SYK-6. *Appl Environ*
1031 *Microbiol* **71**:5014-5021.

1032 67. **Yamamoto Y, Kasai D, Kamimura N, Masai E.** 2012. Isolation and
1033 characterization of *bzaA* and *bzaB* of *Sphingobium* sp. strain SYK-6, which
1034 encode aromatic aldehydes dehydrogenases with different substrate preferences.
1035 *Trans GIGAKU* **1**:01009/01001-01006.

1036 68. **Takeuchi M, Kawai F, Shimada Y, Yokota A.** 1993. Taxonomic study of
1037 polyethylene glycol-utilizing bacteria: emended description of the genus
1038 *Sphingomonas* and new descriptions of *Sphingomonas macrogoltabidus* sp. nov.,
1039 *Sphingomonas sanguis* sp. nov. and *Sphingomonas terrae* sp. nov. *Syst Appl*
1040 *Microbiol* **16**:227-238.

1041 69. **Studier FW, Moffatt BA.** 1986. Use of bacteriophage T7 RNA polymerase to
1042 direct selective high-level expression of cloned genes. *J Mol Biol* **189**:113-130.

1043 70. **Bolivar F, Backman K.** 1979. Plasmids of *Escherichia coli* as cloning vectors.
1044 *Methods Enzymol* **68**:245-267.

1045 71. **Figurski DH, Helinski DR.** 1979. Replication of an origin-containing derivative
1046 of plasmid RK2 dependent on a plasmid function provided in *trans*. *Proc Natl*
1047 *Acad Sci U S A* **76**:1648-1652.

1048 72. **Short JM, Fernandez JM, Sorge JA, Huse WD.** 1988. Lambda ZAP: a
1049 bacteriophage lambda expression vector with in vivo excision properties. *Nucleic*

Acids Res **16**:7583-7600.

73. **Yanisch-Perron C, Vieira J, Messing J.** 1985. Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mpl8 and pUC19 vectors. *Gene* **33**:103-119.
74. **Schäfer A, Tauch A, Jäger W, Kalinowski J, Thierbach G, Pühler A.** 1994. Small mobilizable multi-purpose cloning vectors derived from the *Escherichia coli* plasmids pK18 and pK19: selection of defined deletions in the chromosome of *Corynebacterium glutamicum*. *Gene* **145**:69-73.
75. **Masai E, Sasaki M, Minakawa Y, Abe T, Sonoki T, Miyauchi K, Katayama Y, Fukuda M.** 2004. A novel tetrahydrofolate-dependent *O*-demethylase gene is essential for growth of *Sphingomonas paucimobilis* SYK-6 with syringate. *J Bacteriol* **186**:2757-2765.
76. **Blatny JM, Brautaset T, Winther-Larsen HC, Karunakaran P, Valla S.** 1997. Improved broad-host-range RK2 vectors useful for high and low regulated gene expression levels in gram-negative bacteria. *Plasmid* **38**:35-51.
77. **Masai E, Yamamoto Y, Inoue T, Takamura K, Hara H, Kasai D, Katayama Y, Fukuda M.** 2007. Characterization of *ligV* essential for catabolism of vanillin by *Sphingomonas paucimobilis* SYK-6. *Biosci Biotechnol Biochem* **71**:2487-2492.

Figure Legends

FIG 1 Proposed catabolic pathway of arylglycerol- β -aryl ether in *Sphingobium* sp.

strain SYK-6. The pathway for both guaiacyl (R = H) and syringyl (R = OCH₃)-type β -aryl ether compounds is shown. Enzymes: LigD, LigL, and LigN, C α -dehydrogenases; LigF, LigE, and LigP, β -etherases; LigG, glutathione *S*-transferase; HpvZ, HPV oxidase; ALDHs, aldehyde dehydrogenases; Abbreviations: GGE, guaiacylglycerol- β -guaiacyl ether; MPHPV, α -(2-methoxyphenoxy)- β -hydroxypropiovanillone; GS-HPV, α -glutathionyl- β -hydroxypropiovanillone; HPV, β -hydroxypropiovanillone; HPS, β -hydroxypropiosyringone; VAL, vanilloyl acetaldehyde; SAL, 3-(4-hydroxy-3,5-dimethoxyphenyl)-3-oxopropanal; VAA, vanilloyl acetic acid; SAA, 3-(4-hydroxy-3,5-dimethoxyphenyl)-3-oxopropanoic acid; CoA, coenzyme A; VAA-CoA, CoA derivative of VAA.

FIG 2 HPLC-MS analysis of HPV metabolites. Resting cells of SYK-6 (OD₆₀₀ of 5.0) and SYK-6 cell extracts (>10 kDa; 500 μ g of protein/ml) were incubated with 1 mM HPV (A and B) and 200 μ M HPV (D and E), respectively. The same cell extracts (>10 kDa) were incubated with HPV in the presence of 500 μ M NAD⁺ (G and H) and in the presence of 500 μ M NAD⁺ + 2 mM CoA + 2.5 mM MgSO₄ + 2.5 mM ATP (J and K). Portions of the reaction mixtures were collected at the start (A and D) and after 2 h (G and J), 6 h (B), and 24 h (E, H, and K) of incubation, and analyzed by HPLC. ESI-MS spectra of compounds I (negative mode), II (positive mode), III (negative mode), and IV (positive mode) are shown in panels C, F, I, and L, respectively. An asterisk shown in panel (I) indicates an unidentified MS fragment that appeared between retention times of 2.0 and 7.0 min in the HPLC chromatogram (H).

FIG 3 HPLC-MS analysis of HPS metabolites. SYK-6 resting cells (OD₆₀₀ of 5.0) and SYK-6 cell extracts (>10 kDa; 500 µg of protein/ml) were incubated with 1 mM HPS (A and B) and 200 µM HPS (D and E), respectively. The same cell extract (>10 kDa) was incubated with HPS in the presence of 500 µM NAD⁺ (G and H). Portions of the reaction mixtures were collected at the start (A, D, and G) and after 4 h (B) and 16 h (E and H) of incubation, and analyzed by HPLC. Negative-ion ESI-MS spectra of compounds V, VI, and VII are shown in panels C, F, and I, respectively.

FIG 4 Function and role of *hvpZ* in SYK-6. (A and B) Conversion of 200 µM HPV by resting cells of *E. coli* harboring pCold12830 and pTf16 in Tris-HCl buffer (pH 7.5) (A) and water (B). Portions of the reaction mixtures were collected after 6 h of incubation, and analyzed by HPLC. ESI-MS spectra of compound VIII (positive mode) is shown in panel C. (D–F) Conversions of 200 µM HPV (D), GGE (E), and HPS (F) by resting cells of SYK-6 (open symbols) and SME059 (closed symbols). Circles, triangles, and diamonds indicate the concentrations of HPV, GGE, and HPS, respectively. (G) Complementation of SME059 with pJB12830. Cells of SYK-6 harboring pJB864 (circles), SME059 harboring pJB864 (triangles), and SME059 harboring pJB12830 (diamonds) were incubated with 200 µM HPV. Experiments shown in panels D–G were performed in triplicate, and the data represent the averages ± standard deviations.

FIG 5 Identification of ALDH genes involved in VAL conversion. (A) Resting cells of *E. coli* carrying each of the 23 SYK-6 ALDH genes (OD₆₀₀ of 1.0) were incubated with 100 µM HPV in the presence of resting cells of *E. coli* harboring pCold12830 and

pTf16 (OD₆₀₀ of 5.0). The amounts of VAA produced in the reaction mixtures containing each of the ALDH gene-expressing cells are shown as the relative ratio to that in the reaction mixture containing SLG_20400-expressing cells. ND, VAA was not detected. (B) Time course of the production of VAA during incubation of 100 μ M HPV with cells of *E. coli* harboring pCold12830 and pTf16 (OD₆₀₀ of 10.0) and *E. coli* carrying following ALDH genes (OD₆₀₀ of 1.0): SLG_20400 (closed circles), SLG_07270 (closed triangles), *bzaB* (closed squares), SLG_12800 (closed diamonds), SLG_18210 (open circles), *bzaA* (open triangles), and SLG_31150 (open squares). *E. coli* cells harboring pET-21a(+) was used as a negative control (open diamonds). (C) Accumulation of VAL-Tris during incubation of 1 mM HPV with cells of *E. coli* harboring pCold12830 and pTf16 (OD₆₀₀ of 10.0) and the following mutants of the ALDH genes (OD₆₀₀ of 0.5): SME061 (Δ SLG_20400; closed circles), SME045 (Δ *bzaB*; closed squares), SME092 (Δ SLG_07270; closed triangles), and SME031 (Δ SLG_12800; closed diamonds). SYK-6 cells were used as a control (open diamonds). These experiments were performed in triplicate, and the data represent the averages \pm standard deviations.

FIG 6 Conversion of VAA by *desV ligV* double mutant. Resting cells of *desV ligV* double mutant (SME077) were incubated with 100 μ M VAA (A–C) and 1 mM ferulate (D–F). Portions of the reaction mixtures were collected at the start (A and D) and after 2 h (B and E) and 4 h (C and F) of incubation, and analyzed by HPLC using two different analytical conditions described in the materials and methods. The retention times of vanillin separated under the analytical conditions for the reaction mixtures of VAA (A–C) and ferulate (D–F) were 2.9 and 2.4 min, respectively.

1142 **FIG 7** Synthetic routes to HPS and HPV.

TABLE 1 Substrate range of HpvZ

Compounds	Specific activity ^a (nmol·min ⁻¹ ·mg ⁻¹)
HPV	26 ± 6
HPS	40 ± 5
coniferyl alcohol	8.0 ± 0.4
sinapyl alcohol	52 ± 7
cinnamyl alcohol	40 ± 9
3-(4-hydroxyphenyl)-1-propanol	8 ± 2
homovanillyl alcohol	ND ^b
vanillyl alcohol	ND
GGE	ND
MPHPV	ND
DCA	13 ± 2
DCA-C	ND

^aThe membrane fraction of *hpvZ* expressing *E. coli* (300 µg of protein/ml) was incubated with 200 µM substrate in the presence of 500 µM PMS. The data represent the averages ± standard deviations of three independent experiments.

^bND, not detected

TABLE 2 Strains and plasmids used in this study

Strains or plasmids	Relevant characteristic(s) ^a	Reference or source
<i>Sphingobium</i> sp.		
SYK-6	Wild type; Nal ^r Sm ^r	(65)
SME009	SYK-6 derivative; <i>ferA::kan</i> ; Nal ^r Sm ^r Km ^r	(36)
SME031	SYK-6 derivative; SLG_12800::kan; Nal ^r Sm ^r Km ^r	(66)
SME045	SYK-6 derivative; <i>bzaB::tet</i> ; Nal ^r Sm ^r Tc ^r	(67)
SME059	SYK-6 derivative; <i>hvpZ::kan</i> ; Nal ^r Sm ^r Km ^r	This study
SME061	SYK-6 derivative; ΔSLG_20400; Nal ^r Sm ^r	This study
SME077	SYK-6 derivative; <i>desV::cat ligV::kan</i> ; Nal ^r Sm ^r Cm ^r Km ^r	(51)
SME092	SYK-6 derivative; SLG_07270::kan; Nal ^r Sm ^r Km ^r	This study
<i>Sphingomonas sanguinis</i>		
IAM 12578	Nal ^r	(68)
<i>Escherichia coli</i>		
BL21(DE3)	F ⁻ <i>ompT hsdS_B(r_B⁻ m_B⁻) gal dcm</i> (DE3); T7 RNA polymerase gene under the control of the <i>lacUV5</i> promoter	(69)
HB101	<i>recA13 supE44 hsd20 ara-14 proA2 lacY1 galK2 rpsL20 xyl-5 mtl-1</i>	(70)
NEB 10-beta	<i>araD139 Δ(ara-leu)7697 fhuA lacX74 galK</i> (φ80 Δ <i>lacZ</i> Δ <i>M15</i>) <i>recA1 endA1 nupG rpsL</i> (Sm ^r) Δ(<i>mrr-hsdRMS-mcrBC</i>)	New England Biolabs
Plasmids		
pVK100	Broad-host-range cosmid vector; Km ^r Tc ^r	(62)
pRK2013	Tra ⁺ Mob ⁺ ColE1 replicon; Km ^r	(71)
pT7Blue	Cloning vector; Ap ^r	Novagen
pBluescript II KS(+) and SK(+)	Cloning vector; Ap ^r	(72)
pUC19	Cloning vector; Ap ^r	(73)
pET-16b	Expression vector; T7 promoter, Ap ^r	Novagen
pET-21a(+)	Expression vector; T7 promoter, Ap ^r	Novagen
pCold I	Expression vector; <i>cspA</i> promoter, Ap ^r	Takara Bio
pTf16	Expression vector for <i>tig</i> ; <i>araB</i> promoter; Cm ^r	Takara Bio
pK18 <i>mobsacB</i>	<i>oriT sacB</i> ; Km ^r	(74)
pK19 <i>mobsacB</i>	<i>oriT sacB</i> ; Km ^r	(74)
pIK03	KS(+) with a 1.3-kb EcoRV fragment carrying <i>kan</i> of pUC4K; Ap ^r Km ^r	(75)
pJB864	RK2 broad-host-range expression vector; Ap ^r Cb ^r P _m <i>xylS</i>	(76)
pAK405	Plasmid for allelic exchange and markerless gene deletions in <i>Sphingomonads</i> ; Km ^r	(64)
pSA53	pVK100 with partially SalI-digested fragments of SYK-6 carrying <i>hvpZ</i>	This study
pSA88	pVK100 with partially SalI-digested fragments of SYK-6 carrying <i>hvpZ</i>	This study
pSA684	pVK100 with partially SalI-digested fragments of SYK-6 carrying <i>hvpZ</i>	This study
pT7B12830	pT7Blue with a 1.7-kb PCR amplified fragment carrying <i>hvpZ</i>	This study
pCold12830	pCold I with a 1.7-kb NdeI-BamHI fragment carrying <i>hvpZ</i> from pT7B12830	This study
pBH37F	SK(+) with a 3.7-kb HindIII fragment carrying <i>hvpZ</i> from pSA53	This study
pUC12830	pUC19 with a 2.0-kb SalI fragment of pBH37F	This study
pUC12830K	pUC12830 with a 1.3-kb SalI-BamHI fragment of pIK03 carrying <i>kan</i>	This study
pKmb12830K	pK19 <i>mobsacB</i> with a 3.1-kb SalI fragment of pUC12830K	This study
pJB12830	pJB864 with a 2.3-kb BamHI-SacII (blunted) fragment carrying <i>hvpZ</i> from pBH37F	This study
pLVH	pET-21a(+) with a 1.9-kb NdeI-XhoI fragment carrying <i>ligV</i>	(77)
pT21-0727	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_07270	(51)
pT21-0761	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_07610	(51)
pT21-0779	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_07790	(51)
pT21-0940	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_09400	(51)
pT21-0951	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_09510	(51)
pT21-0992	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_09920	(51)
pT21-1141	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_11410	(51)
pT21-1202	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_12020	(51)
pT21-1219	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_12190	(51)
pT21-1280	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_12800	(51)
pT21-1821	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_18210	(51)
pT21-2040	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_20400	(51)

pT21-2721	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_27210	(51)
pT21-2791	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying <i>bzaA</i>	(51)
pT21-2792	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying <i>bzaB</i>	(51)
pT21-2815	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_28150	(51)
pT21-2832	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_28320	(51)
pT21-3115	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_31150	(51)
pT21-3224	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_32240	(51)
pT21-3494	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_34940	(51)
pT21-3812	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_38120	(51)
pT21-p0068	pET-21a(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_p_00680	(51)
pKS0727	KS(+) with a 1.5-kb NdeI-BamHI fragment carrying SLG_07270	(51)
pKmb07270	pK18 <i>mobsacB</i> with a 1.5-kb HindIII-XbaI carrying SLG_07270 from pKS0727	This study
pKmb07270K	pKmb07270 with a 1.3-kb EcoRV fragment carrying <i>kan</i> from pIK03 into NruI site of SLG_07270	This study
pAK20400	pAK405 with a 2.3-kb deletion cassette carrying up- and downstream regions of SLG_20400	This study
pE16FA	pET-16b with a 2.2-kb NdeI-BamHI fragment carrying <i>ferA</i>	(31)
pE16FB	pET-16b with a 0.9-kb NdeI-BamHI PCR amplified fragment carrying <i>ferB</i>	This study
pE16FB2	pET-16b with a 1.1-kb NdeI-BamHI PCR amplified fragment carrying <i>ferB2</i>	This study

^a Km^r, NaI^r, Sm^r, Ap^r, Tc^r, Cm^r, and Cb^r, resistance to kanamycin, nalidixic acid, streptomycin, ampicillin, tetracycline, chloramphenicol, and carbenicillin, respectively.

TABLE 3 Primer sequences used for construction of plasmids and colony PCR

Plasmid or strain	Primer	Sequence (5' to 3')
Construction of plasmids		
pT7B12830	12830_pT7B_F	AGACAGGCATATGGTTGATG
	12830_pT7B_R	GGGCGGCATGGATCCGC
pAK20400	dis20400_Top_F	CGGTACCCGGGGATCCGGCTTCGGTGACAATCAT
	dis20400_Top_R	ATGTCCGTGGTGTCTGCGT
	dis20400_Bot_F	ACGCAGAACACCACGGACATTCTCCCCGTGATGACCTAT
	dis20400_Bot_R	CGACTCTAGAGGATCGTGGCGGCATCAACATATCG
pE16FB	ferB_exp_F	GGAAAATCATATGTCCGAGG
	ferB_exp_R	ATACTGGCGGATCCAGCC
pE16FB2	ferB2_exp_F	TGAGGATGCATATGTCCGATG
	ferB2_exp_R	GCCGGATCCCGGAATGC
Colony PCR		
SME061	dis20400_conf_F	CCTTCATCGCCATCATAAAT
	dis20400_Bot_R	CGACTCTAGAGGATCGTGGCGGCATCAACATATCG